WO2015155753A2 - Nouvelles séquences de liaison et leurs utilisation pour la conjugaison spécifique de médicaments à une molécule biologique - Google Patents

Nouvelles séquences de liaison et leurs utilisation pour la conjugaison spécifique de médicaments à une molécule biologique Download PDF

Info

Publication number
WO2015155753A2
WO2015155753A2 PCT/IB2015/056083 IB2015056083W WO2015155753A2 WO 2015155753 A2 WO2015155753 A2 WO 2015155753A2 IB 2015056083 W IB2015056083 W IB 2015056083W WO 2015155753 A2 WO2015155753 A2 WO 2015155753A2
Authority
WO
WIPO (PCT)
Prior art keywords
cell
drug
receptor
conjugate
antibody
Prior art date
Application number
PCT/IB2015/056083
Other languages
English (en)
Other versions
WO2015155753A3 (fr
Inventor
Robert Yongxin Zhao
Robert Zhao
Original Assignee
Suzhou M-Conj Biotech Co., Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suzhou M-Conj Biotech Co., Ltd filed Critical Suzhou M-Conj Biotech Co., Ltd
Priority to JP2018506984A priority Critical patent/JP6817288B2/ja
Priority to CA2991975A priority patent/CA2991975C/fr
Priority to CN202210788010.0A priority patent/CN115300640A/zh
Priority to CN201580082582.5A priority patent/CN108289964B/zh
Priority to PCT/IB2015/056083 priority patent/WO2015155753A2/fr
Publication of WO2015155753A2 publication Critical patent/WO2015155753A2/fr
Publication of WO2015155753A3 publication Critical patent/WO2015155753A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/26—Oxygen atoms attached in position 2 with hetero atoms or acyl radicals directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/60—Two oxygen atoms, e.g. succinic anhydride
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes

Definitions

  • the present invention relates to linkers used for the specific conjugation of compounds, in particular, cytotoxic agents to pairs of sulfur atoms of a biological molecule at two drugs per linker.
  • the present invention also relates to methods of making cell-binding agent-drug (cytotoxic agent) conjugates in a specific manner comprising either modification of drugs with these linkers first, followed by reaction with prepared cell-binding agents; or modification of cell-binding agents with these linkers first, followed by reaction with drugs.
  • chemotherapeutic drugs are their narrow therapeutic windows due to they normally cannot discriminate between normal and malignant cells, thus causes side effects which limit the tolerated doses below the clinically effective ones.
  • immunotherapy normally in the form of monoclonal antibodies (mAb) can specifically bind to certain proteins or molecules of malignant cells, leaving normal cells unharmed, and thus has less side effects and bigger therapeutic windows than chemotherapy.
  • Monoclonal antibodies (mAb) can target against malignant cells by several mechanisms, such as, 1). Making the cancer cell more visible to the immune system (Villaruz, L. C. et al, 2014, Transl Lung Cancer Res, 3, 2-14; Camacho, L. H. 2015 Cancer Med 4, 661-72); 2).
  • Blocking growth signals (Dillman, R. O. 2011, Cancer Biother Radiopharm, 26, 1-64; Ferris, R. L. et al 2010, J Clin Oncol, 28, 4390-9); 3). Stopping new blood vessels from forming (Arrillaga-Romany, I., et al, 2014, Expert Opin Investig Drugs, 23, 199-210); 4). Delivering radiation to cancer cells (Chapuy, B. et al, 2007, Biotechnol J. 2, 1435-43); 5). Delivering chemotherapy drug to cancer cells (Chari R. J. 2008 Acc Chem Res. 41, 98-107;
  • the first-generation ADCs including Kadcyla and Adcetris, are produced through nonselective conjugation of native lysine amines or interchain cysteine thiols on an antibody respectively to a cytotoxic drug. Since there are over 50 surface-exposed lysines and 8 hinge cysteine residues in IgGl antibodies, this nonselective conjugation results in randomly cross-linkage of cytotoxic drugs to practically all areas of the antibody molecule, particularly having a diverse population of ADCs with a wide distribution of drugs per antibody (DAR) (Wang, L., et al. 2005 Protein Sci. 14, 2436; Hamblett, K. J., et al. 2004 Clin. Cancer Res. 10, 7063).
  • DAR drugs per antibody
  • Disulfide bond structure is critical for the structure, stability, and biological functions of IgG molecules.
  • each IgG contains a total of 12 intra-chain disulfide bonds; each disulfide bond is associated with an individual IgG domain.
  • the two heavy chains are connected in the hinge region by a variable number of disulfide bonds: 2 for IgGi and IgG 4 , 4 for IgG 2 and 11 for IgG 3 .
  • the light chain of the IgGi is connected to the heavy chain by a disulfide bond between the last cysteine residue of the light chain and the fifth cysteine residue of the heavy chain.
  • the light chain is linked to the heavy chain by a disulfide bond between the last cysteine residue of the light chain and the third cysteine residue of the heavy chain (Liu, H. and May, K., 2012, mAbs
  • the upper disulfide bond of the two inter heavy chain disulfide bonds was more susceptible than the lower one. Furthermore, disulfide bonds in the CH2 domain were the most susceptible to reduction. Disulfide bonds in VL, CL, VH, and CHI domains had similar and moderate susceptibility, while disulfide bonds in the CH3 domain were the least susceptible to reduction (Liu, H, et al Anal. Chem., 2010, 82, 5219-5226).
  • next generation maleimides (NGMs) (Schumacher, F.F., et al 2014, Org. Biomol. Chem. 12, 7261-7269; UCL Cancer Institute), applying bis-alkylating reagents via a three-carbon bridge (Badescu, G., et al., 2014, Bioconjug. Chem.
  • bridge linkers were designed in the way to conjugate only one cytotoxic agents to a pair of disulfide bonds, and therefore at most of time they only produced ADCs at DAR less than 2 (drugs per antibody), due to limited numbers (about two pairs) of reduced disulfide bonds are more accessible for conjugation.
  • novel disulfur bridge linkers of this invention that not only are able to conjugate two or more drugs per linker for achieving higher DARs (>4), but also can selectively rebridge pairs of reduced inter chain disulfide bonds on surface of antibody, which are generated by overloaded TCEP or DTT reduction agents. And the over reduced pairs of thiol groups that are inaccessibly reached by the bridge linkers can be recoupled (regenerated) by an oxide, e.g. dehydroascorbic acid (DHAA) or Cu(II), to form back disulfide bonds at the end of conjugation.
  • DHAA dehydroascorbic acid
  • Cu(II) Cu(II
  • the bridge linkers of this invention containing a 2,3-disubstituted succinic group, or 2- monosubstituted, or 2,3-disubstituted fumaric or maleic (trans (E) ⁇ or cis (Zj-butenedioic) group have less payload loss as compared to their nonhydrolyzed bromo or dibromo- maleimide linkers which were tested in our lab.
  • the methods of the instant invention can be used to for the immunoconjugates that carry a combination of drugs, in particular different drugs, which can be delivered simultaneously and specifically to a particular target site, where the therapeutic molecules in the medicament are highly homogeneous, with lot-to-lot consistency.
  • immunoconjugates include: simultaneous targeted delivery of multiple drugs that act synergistically in target- ing malignant cells; combining drugs that act in different phases of the cell cycle to increase the number of target cells exposed to a particular pharmaceutical drug or effect; minimized exposure to non-target cells, tissues or organs; precise control over drug pay- loads and drug ratios leading to homogenous final products.
  • the bridge linkers of the invention can make homogeneous production of specific ADCs in a simple manner.
  • the present invention provides linkers containing a 2,3-disubstituted succinic group, or 2-monosubstituted, or 2,3-disubstituted fumaric or maleic (trans (E)- or cis (Zj- butenedioic) group to link two drugs to a cell-binding agent (e.g., an antibody).
  • a cell-binding agent e.g., an antibody
  • the preferred formula of the cell-binding molecule-linker-drug conjugates can be represented as: , wherein Cb is a cell-binding agent, L Cb is a cell-binding agent, L is a linker containing succinic, fumaric or maleic group; Drugl and Drug2 are a drug molecule; n is an integer from 1 to 30; and two S (sulfur) elements from Cb bridgely link to L, which covalently connects two or more drugs.
  • the advantages in applying the linker in the cell molecule-drug conjugate are: a).
  • the linker is represented by Formula (I)
  • U and LP represent the same or different leaving group that can be substituted by a thiol.
  • Such leaving groups are, but are not limited to, a halide (e.g., fluoride, chloride, bromide, and iodide), methanesulfonyl (mesyl), /?-toluenesulfonyl (tosyl),
  • triflate trifluoromethylsulfonyl
  • trifluoromethylsulfonate nitrophenol, N- hydroxysuccinimide (NHS)
  • phenol dinitrophenol; pentafluorophenol, tetrafluorophenol, difluorophenol, monofluorophenol, pentachlorophenol, imidazole, dichlorophenol, tetrachlorophenol, 1-hydroxybenzotriazole, 2-ethyl-5-phenylisoxazolium-3'-sulfonate, or an intermediate molecule generated with a condensation reagent for Mitsunobu reactions.
  • both U and LP are not H; when represents a double bond, either U or LP can be H, but are not H at the same time.
  • Z 1 and Z 2 are the same or different a function group that enables to react with a cytotoxic drug, to form a disulfide, ether, ester, thioether, thioester, peptide, hydrazone, carbamate, carbonate, amine (secondary, tertiary, or quarter), imine, cycloheteroalkyane, heteroaromatic, alkyloxime or amide bond;
  • R 1 and R 2 are the same or different, and are absent, linear alkyl having from 1-6 carbon atoms, branched or cyclic alkyl having from 3 to 6 carbon atoms, linear, branched or cyclic alkenyl or alkynyl, or 1-6 carbon atoms of esters, ether, amide, or polyethyleneoxy unit of formula (OCH 2 CH 2 ) p , wherein p is an integer from 0 to about 1000, or combination thereof.
  • R 1 and R 2 are respectively a chain of atoms selected from C, N, O, S, Si, and P, preferably having 0-500 atoms, which covalently connects to X 1 or X 2 and Z 1 or Z 2 .
  • the atoms used in forming the R 1 and R 2 may be combined in all chemically relevant ways, such as forming alkylene, alkenylene, and alkynylene, ethers, polyoxyalkylene, esters, amines, imines, polyamines, hydrazines, hydrazones, amides, ureas,
  • semicarbazides carbazides, alkoxyamines, alkoxylamines, urethanes, amino acids, peptides, acyloxylamines, hydroxamic acids, or combination thereof.
  • X 1 and X 2 are independently selected from NH, N(R 3 ), O, S or C H 2 ;
  • R 3 is H, linear al- kyl having from 1-6 carbon atoms, branched or cyclic alkyl having from 3 to 6 carbon atoms, linear, branched or cyclic alkenyl or alkynyl, or 1-6 carbon atoms of esters, ether, amide, or polyethyleneoxy unit of formula H 2 H 2 )p, wherein p is an integer from 0 to about 1000, or combination thereof.
  • this invention provides a cell-binding agent-drug conjugate of Formula (II), in which the cell-binding agent, Cb, and the drug, Drugl and Drug2, have reacted at the ends of the bridge linker:
  • Cb represents a cell-binding agent, preferred an antibody
  • the linker-drug components that are conjugated to pairs of sulfur atoms of the cell-binding molecule.
  • the sulfur atoms are preferred pairs of thiols reduced from the interchain disulfide bonds of the cell-binding agent by a reduction agent, such as DTT and/or TCEP;
  • Drug 1 and Drug 2 represent the same or different cytotoxic agents, which linked to the cell-binding agent via the bridge linker by a disulfide, thioether, thioester, peptide, hydra- zone, ether, ester, carbamate, carbonate, cycloheteroalkyane, heteroaromatic, alkoxime or amide bond; are described the same previously in
  • the present invention provides a modified cell-binding agent of Formula (III), in which the cell-binding agent, Cb, through its pair of thiols generated with reduction of disulfide bonds, has reacted with the bridge linker, which has Z 1 and Z 2 , the function groups capable of reacting with a drug:
  • the present invention provides a modified drug of Formula
  • Drug 1 , Drug 2 , U, U', R 1 , R 2 , X 1 , and X 2 are defined the same as in Formula (I) and (II).
  • the present invention further relates to a method of making a cell-binding molecule- drug conjugate of Formula (II), wherein the drugs, Drug 1 and Drug 2 are linked to a cell- binding agent via the bridge linker.
  • the present invention also relates to a method of making a modified cell-binding molecule of Formula (III), wherein the cell-binding molecule is reacted with the bridge linker of Formula (I).
  • the present invention also relates to a method of making a modified drug of formula (IV), wherein the drug is reacted with the bridge linker of Formula (I).
  • Figure 1 shows the synthesis of a bridge linker containing polyethylene glycols and the application of this linker in the conjugation of an antibody with drugs via amide bonds.
  • Figure 2 shows the synthesis of a bridge linker containing polyethylene glycols and the application of this linker in the conjugation of drugs to an antibody via amide bonds.
  • Figure 3 shows the synthesis of a bridge linker containing polyethylene glycols and the application of this linker in the conjugation of drugs to an antibody via oxime linkage.
  • Figure 4 shows the synthesis of a bridge linker containing polyethylene glycols and the application of this linker in the conjugation of two drugs to an antibody via hydrazone linkage.
  • Figure 5 shows the synthesis of bridge linkers containing polyethylene glycols and the application in the conjugation of two different drugs per linker to an antibody via amide linkage.
  • Figure 6 shows the synthesis of bridge linkers and the application in the conjugation of two different drugs per linker to an antibody via hinder amide linkage.
  • Figure 7 shows the synthesis of bridge linkers containing peptides or polyethylene glycols and the application of these linkers in the conjugation of two (different) drugs to an antibody via hydrazone linkage.
  • Figure 8 shows the synthesis of the conjugatable analogs of MMAE, Tubulysin and PBD cytotoxic drugs.
  • Figure 9 shows the synthesis of the conjugatable analogs of PBD, MMAF, and Tubulysin D cytotoxic drugs.
  • Figure 10 shows the synthesis of the conjugates of cell-binding molecule-tubulysin analogs via the bridge-linker.
  • Figure 11 shows the synthesis of the conjugates of both PBD dimer analog and Tubulysin B analog per linker, or both MMAE and Tubulysin D analog per linker, to an antibody.
  • Figure 12 shows the synthesis of the conjugates of both PBD dimer analog
  • MMAF analog per linker or both PBD dimer and Tubulysin B analog per linker, to an antibody.
  • Figure 13 shows the synthesis of the conjugates of both Maytansinoid analog and Tubulysin B analog per linker, to an antibody.
  • Figure 14 shows the synthesis of the conjugates of both Maytansinoid analog
  • PBD dimer analog per linker or two Tubulysin B analogs per linker, to an antibody.
  • Figure 15 shows the synthesis of the conjugates of both two MMAF analogs per linker, or two Tubulysin B analogs per linker, containing polyethylene glycols, to an antibody
  • Figure 16 shows the comparison of the anti-tumor effect of conjugate compounds 127, 129 and 142 with T-DM1 using human gastric tumor N87 cell model at dosing, 3 mg/kg, i.v., one injection. All the four conjugates did not cause the animal body weight loss (top figure). The animals at control group were sacrificed at day 37 due to the tumor volume larger than 1500 mm and they were too sick.
  • the three compounds 127, 129 and 142 were better than T-DM1: All 6/6 animals at the groups of compound 127 and 129 had completely no tumor measurable at day 13 till day 60 (the end of experiment). All 6/6 animals at the group of Compound 142 group had no tumor measurable at day 21 and 2/6 animals had tumor growth (measurable) back at days 48, which still inhibited the tumor growth for over 55 days. In contrast T-DM1 at dose of 3 mg/Kg was not able to eradicate the tumors completely although it had inhibited the tumor growth for about 28 days.
  • Alkyl refers to an aliphatic hydrocarbon group which may be straight or branched having 1 to 8 carbon atoms in the chain. "Branched” means that one or more lower C numbers of alkyl groups such as methyl, ethyl or propyl are attached to a linear alkyl chain.
  • alkyl groups include methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, n-pentyl, 3-pentyl, octyl, nonyl, decyl, cyclopentyl, cyclohexyl, 2,2-dimethylbutyl, 2,3- dimethylbutyl, 2,2-dimethylpentyl, 2,3-dimethylpentyl, 3,3-dimethylpentyl, 2,3,4- trimethylpentyl, 3-methyl-hexyl, 2,2-dimethylhexyl, 2,4-dimethylhexyl, 2,5- dimethylhexyl, 3,5-dimethylhexyl, 2,4-dimethylpentyl, 2-methylheptyl, 3-methylheptyl, n- heptyl, isoheptyl, n-octyl, and isooct
  • a C 1 -C 8 alkyl group can be unsubstituted or substituted with one or more groups including, but not limited to, -C 1 -C 8 alkyl,-O-(C 1 -C 8 alkyl), -aryl, -C(O)R', -OC(O)R', -C(O)OR', -C(O)NH 2 , -C(O)NHR', -C(O)N(R') 2 , -NHC(O)R', - SR', -S(O) 2 R', -S(O)R', -OH, -halogen, -N 3 , -NH 2 , -NH(R'), -N(R') 2 and -CN; where each
  • R' is independently selected from -C 1 -C 8 alkyl and aryl.
  • Halogen refers to fluorine, chlorine, bromine or iodine atom; preferably fluorine and chlorine atom.
  • Heteroalkyl refers to C 2 -C 8 alkyl in which one to four carbon atoms are inde- pendently replaced with a heteroatom from the group consisting of O, S and N.
  • Carbocycle refers to a saturated or unsaturated ring having 3 to 8 carbon atoms as a monocycle or 7 to 13 carbon atoms as a bicycle.
  • Monocyclic carbocycles have 3 to 6 ring atoms, more typically 5 or 6 ring atoms.
  • Bicyclic carbocycles have 7 to 12 ring atoms, arranged as a bicycle [4,5], [5,5], [5,6] or [6,6] system, or 9 or 10 ring atoms arranged as a bicycle [5,6] or [6,6] system.
  • Representative C 3 -C 8 carbocycles include, but are not limited to, -cyclopropyl, -cyclobutyl, -cyclopentyl, -cyclopentadienyl, -cyclohexyl, -cyclohexenyl, -1,3-cyclohexadienyl, -1,4-cyclohexadienyl, -cycloheptyl, -1,3-cycloheptadienyl, -1,3,5- cycloheptatrienyl, -cyclooctyl, and -cyclooctadienyl.
  • a "C 3 -C 8 carbocycle” refers to a 3-, 4-, 5-, 6-, 7- or 8-membered saturated or unsaturated nonaromatic carbocyclic ring.
  • a C 3 -C 8 carbocycle group can be unsubstituted or substituted with one or more groups including, but not limited to, -C 1 -C 8 alkyl,-O-(C 1 -C 8 alkyl), -aryl, -C(O)R', -OC(O)R', -C(O)OR', -C(O)NH 2 , -C(O)NHR', -C(O)N(R') 2 , - NHC(O)R', -SR', -S(O)R',-S(O) 2 R', -OH, -halogen, -N 3 , -NH 2 , -NH(R'), -N(R') 2 and -CN; where each R
  • alkenyl refers to an aliphatic hydrocarbon group containing a carbon-carbon double bond which may be straight or branched having 2 to 8 carbon atoms in the chain.
  • alkenyl groups include ethenyl, propenyl, n-butenyl, i-butenyl, 3-methylbut-2-enyl, n-pentenyl, hexylenyl, heptenyl, octenyl.
  • Alkynyl refers to an aliphatic hydrocarbon group containing a carbon-carbon triple bond which may be straight or branched having 2 to 8 carbon atoms in the chain.
  • exemplary alkynyl groups include ethynyl, propynyl, n-butynyl, 2-butynyl, 3-methylbutynyl, 5- pentynyl, n-pentynyl, hexylynyl, heptynyl, and octynyl.
  • Alkylene refers to a saturated, branched or straight chain or cyclic hydrocarbon rad- ical of 1-18 carbon atoms, and having two monovalent radical centers derived by the removal of two hydrogen atoms from the same or two different carbon atoms of a parent alkane.
  • Typical alkylene radicals include, but are not limited to: methylene (-CH 2 -), 1,2- ethyl (-CH 2 CH 2 -), 1,3-propyl (-CH 2 CH 2 CH 2 -), 1,4-butyl (-CH 2 CH 2 CH 2 CH 2 -), and the like.
  • Alkenylene refers to an unsaturated, branched or straight chain or cyclic hydrocarbon radical of 2-18 carbon atoms, and having two monovalent radical centers derived by the removal of two hydrogen atoms from the same or two different carbon atoms of a parent alkene.
  • Alkynylene refers to an unsaturated, branched or straight chain or cyclic hydrocarbon radical of 2-18 carbon atoms, and having two monovalent radical centers derived by the removal of two hydrogen atoms from the same or two different carbon atoms of a parent alkyne.
  • Typical alkynylene radicals include, but are not limited to: acetylene, propargyl and 4-pentynyl.
  • Aryl or Ar refers to an aromatic or hetero aromatic group, composed of one or several rings, comprising three to fourteen carbon atoms, preferentially six to ten carbon atoms.
  • hetero aromatic group refers one or several carbon on aromatic group, preferentially one, two, three or four carbon atoms are replaced by O, N, Si, Se, P or S, preferentially by O, S, and N.
  • Heterocycle refers to a ring system in which one to four of the ring carbon atoms are independently replaced with a heteroatom from the group of O, N, S, Se, B, Si and P. Preferable heteroatoms are O, N and S. Heterocycles are also described in The Handbook of Chemistry and Physics, 78th Edition, CRC Press, Inc., 1997-1998, p. 225 to 226, the disclosure of which is hereby incorporated by reference.
  • Preferred nonaromatic heterocyclic include, but are not limited to epoxy, aziridinyl, thiiranyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, oxiranyl, tetrahydrofuranyl, dioxolanyl, tetrahydropyranyl, dioxanyl, dioxolanyl, piperidyl, piperazinyl, morpholinyl, pyranyl, imidazolinyl, pyrrolinyl, pyrazolinyl, thiazolidinyl, tetrahydrothiopyranyl, dithianyl, thiomorpholinyl,
  • dihydropyranyl tetrahydropyranyl, dihydropyranyl, tetrahydropyridyl, dihydropyridyl, tetrahydropyrimidinyl, dihydrothiopyranyl, azepanyl, as well as the fused systems resulting from the condensation with a phenyl group.
  • heteroaryl refers to a 5 to 14, preferably 5 to 10 membered aromatic hetero, mono-, bi- or multicyclic ring.
  • examples include pyrrolyl, pyridyl, pyrazolyl, thienyl, pyrimidinyl, pyrazinyl, tetrazolyl, indolyl, quinolinyl, purinyl, imidazolyl, thienyl, thiazolyl, benzothiazolyl, furanyl, benzofuranyl, 1,2,4-thiadiazolyl, isothiazolyl, triazoyl, tetrazolyl, isoquinolyl, benzothienyl, isobenzofuryl, pyrazolyl, carbazolyl, benzimidazolyl, isoxazolyl, pyridyl-N-oxide, as well as the fused systems resulting from the condensation with a phenyl group.
  • Alkyl refers also to the corresponding "alkylene”, “cycloalkylene”, “alkenylene”, “alkynylene”, “arylene”, “heteroarylene”, “heterocyclene” and the likes which are formed by the removal of two hydrogen atoms.
  • Arylalkyl refers to an acyclic alkyl radical in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or sp carbon atom, is replaced with an aryl radical.
  • Typical arylalkyl groups include, but are not limited to, benzyl, 2-phenylethan-l- yl, 2-phenylethen-l-yl, naphthylmethyl, 2-naphthylethan-l-yl, 2-naphthylethen-l-yl, naphthobenzyl, 2-naphthophenylethan-l-yl and the like.
  • Heteroarylalkyl refers to an acyclic alkyl radical in which one of the hydrogen at- oms bonded to a carbon atom, typically a terminal or sp carbon atom, is replaced with a heteroaryl radical.
  • Typical heteroarylalkyl groups include, but are not limited to, 2- benzimidazolylmethyl, 2-furylethyl and the like.
  • hydroxyl protecting group examples include, but are not limited to, methoxymethyl ether, 2-methoxyethoxymethyl ether, tetrahydropyranyl ether, benzyl ether, /?-methoxybenzyl ether, trimethylsilyl ether, triethylsilyl ether, triisopropylsilyl ether, i-butyldimethylsilyl ether, triphenylmethylsilyl ether, acetate ester, substituted acetate esters, pivaloate, benzoate, methanesulfonate and /?-toluenesulfonate.
  • leaving group refers to a functional group that can be substituted by another func- tional group. Such leaving groups are well known in the art, and examples include, but are not limited to, a halide (e.g., chloride, bromide, and iodide), methanesulfonyl (mesyl), /?- toluenesulfonyl (tosyl), trifluoromethylsulfonyl (triflate), and trifluoromethyl sulfonate.
  • a halide e.g., chloride, bromide, and iodide
  • methanesulfonyl meyl
  • /?- toluenesulfonyl tosyl
  • triflate trifluoromethylsulfonate
  • Boc ie/ -butoxy carbonyl
  • BroP bromotrispyrrolidinophosphonium hexafluorophosphate
  • CDI ⁇ , ⁇ -carbonyldiimidazole
  • DCC dicyclohexylcarbodiimide
  • DCE dichloroethane
  • DCM dichloromethane
  • DIAD diisopropylazodicarboxylate
  • DIBAL-H diisobutyl- aluminium hydride
  • DIPEA diisopropylethylamine
  • DEPC diethyl phosphorocyanidate
  • DMA ⁇ , ⁇ -dimethyl acetamide
  • DMAP 4-(7V, N-dimethylamino)pyridine
  • DMF N,N- dimethylformamide
  • DMSO dimethylsulfoxide
  • DTT dithiothreitol
  • EDC l-(3- dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
  • ESI-MS electrospray mass spectrometry
  • HATU O-(7-azabenzotriazol-l-yl)-N, N, N' , N'-tetramethyluronium hexafluorophosphate
  • HOBt 1-hydroxybenzotriazole
  • “Pharmaceutically” or “pharmaceutically acceptable” refer to molecular entities and compositions that do not produce an adverse, allergic or other untoward reaction when administered to an animal, or a human, as appropriate.
  • “Pharmaceutically acceptable solvate” or “solvate” refer to an association of one or more solvent molecules and a disclosed compound. Examples of solvents that form pharmaceutically acceptable solvates include, but are not limited to, water, isopropanol, etha- nol, methanol, DMSO, ethyl acetate, acetic acid and ethanolamine.
  • “Pharmaceutically acceptable excipient” includes any carriers, diluents, adjuvants, or vehicles, such as preserving or antioxidant agents, fillers, disintegrating agents, wetting agents, emulsifying agents, suspending agents, solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like.
  • preserving or antioxidant agents such as preserving or antioxidant agents, fillers, disintegrating agents, wetting agents, emulsifying agents, suspending agents, solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like.
  • the use of such media and agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions as suitable therapeutic combinations.
  • pharmaceutically acceptable salts refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof.
  • the pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids.
  • such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, tartaric, citric, methanesulfonic, benzenesulfonic, glucuronic, glutamic, benzoic, salicylic, toluenesulfonic, oxalic, fumaric, maleic, lactic and the like.
  • Further addition salts include ammonium salts such as tromethamine, meglumine, epolamine, etc., metal salts such as sodium, potassium, calcium, zinc or magnesium.
  • the pharmaceutical salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods.
  • such salts can be prepared via reaction the free acidic or basic forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two.
  • non-aqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 17 th ed., Mack Publishing Company, Easton, PA, 1985, p. 1418, the disclosure of which is hereby incorporated by reference.
  • administering refers to any mode of transferring, delivering, introducing or transporting a pharmaceutical drug or other agent to a subject. Such modes include oral administration, topical contact, intravenous, intraperitoneal, intramuscular, intralesional, intranasal, subcutaneous or intrathecal administration. Also contemplated by the present invention is utilization of a device or instrument in administering an agent. Such device may utilize active or passive transport and may be slow-release or fast-release delivery device.
  • novel conjugates disclosed herein use the bridge linkers. Examples of some suitable linkers and their synthesis are shown in Figures 1 to 15.
  • the synthetic routes to produce bridge linkers as well as the preparation of the conjugates of drugs to a cell binding molecules of the present invention are shown in Figures 1- 15.
  • the bridge linkers possess two elements: a) A Substituent that is a 2,3-disubstituted succinic group; or 2-monosubstituted, or 2,3-disubstituted fumaric group; or 2- monosubstituted, or 2,3-disubstituted maleic group; which can react to a pair of thiols to form covalent thioether bonds, and b) A group, such as but not limited to, a disulfide, maleimide, haloacetyl, aldehyde, ketone, azide, amine, alkoxyamine, hydrazide, ethenesulfonyl, acyl halide (acid halide), acryl (acryloyl), and/or acid anhydride group, capable of reaction with a drug
  • the bridge substituents of 2,3-disubstituted succinic group; or 2-monosubstituted, or 2,3-disubstituted fumaric group; or 2-monosubstituted, or 2,3- disubstituted maleic group can be introduced by direct condensation of these 2,3- disubstituted succinic acid, or 2-monosubstituted or 2,3-disubstituted fumaric or maleic with an amine, an alcohol, or a thiol group to form amide, ester or thioester bonds.
  • the synthesis of these bridge linkers is exampled in the Figures 1, 3, 4, 5, 6, 7, 10, 11, 12, 13, 14 and 15.
  • the bridge linkers are compounds of the Formula (I) below:
  • both U and LP are not H; when represents a double bond, either U or LP can be H, but are not H at the same time.
  • the component: which can be 2,3-disubstituted succinic group, or 2-monosubstituted or 2,3-disubstituted fumaric group, or 2- monosubstituted or 2,3-disubstituted maleic group, is capable of reacting with a pair of sulfur atoms of the cell-binding agent;
  • the sulfur atoms are preferred pairs of thiols re- prised from the interchain disulfide bonds of the cell-binding agent by a reducing agent, such as dithiothreitol (DTT), dithioerythritol (DTE), L-glutathione (GSH) and tris (2- carboxyethyl) phosphine (TCEP), or/and beta mercaptoethanol ( ⁇ - ⁇ , 2-ME
  • U and U' represent the same or different leaving group that can be substituted by a thiol.
  • Such leaving groups are, but are not limited to, a halide (e.g., fluoride, chloride, bromide, and iodide), methanesulfonyl (mesyl), p-toluenesulfonyl (tosyl), trifluoromethyl- sulfonyl (triflate), trifluoromethylsulfonate, nitrophenol, N-hydroxysuccinimide (NHS), phenol; dinitrophenol; pentafluorophenol, tetrafluorophenol, difluorophenol,
  • a halide e.g., fluoride, chloride, bromide, and iodide
  • methanesulfonyl methanesulfonyl
  • p-toluenesulfonyl tosyl
  • triflate trifluoro
  • Z 1 and Z 2 are the same or different a function group that enables to react with a cytotoxic drug, to form a disulfide, thioether, thioester, peptide, hydrazone, ether, ester, carbamate, carbonate, amine (secondary, tertiary, or quarter), imine, cycloheteroalkyane, heteroaromatic, alkoxime or amide bond;
  • R 1 and R 2 are the same or different, and are absent, linear alkyl having from 1-6 carbon atoms, branched or cyclic alkyl having from 3 to 6 carbon atoms, linear, branched or cyclic alkenyl or alkynyl, or 1-6 carbon atoms of esters, ether, amide, or polyethyleneoxy unit of formula (OCH 2 CH 2 ) p , or polypropyleneoxy unit of formula (OCH 2 (CH3)CH 2 ) p wherein p is an integer from 0 to about 1000, or combination thereof.
  • R 1 and R 2 are respectively a chain of atoms selected from C, N, O, S, Si, and P, preferably having 0-500 atoms, which covalently connects to X 1 or X 2 and Z 1 or Z 2 .
  • the atoms used in forming the R 1 and R 2 may be combined in all chemically relevant ways, such as forming alkylene, alkenylene, and alkynylene, ethers, polyoxyalkylene, esters, amines, imines, polyamines, hydrazines, hydrazones, amides, ureas,
  • X 1 and X 2 are independently selected from NH, N(R 3 ), O, S or CH 2 ; Wherein R 3 is H, linear alkyl having from 1-6 carbon atoms, branched or cyclic alkyl having from 3 to 6 carbon atoms, linear, branched or cyclic alkenyl or alkynyl, or 1-6 carbon atoms of esters, ether, amide, or polyethyleneoxy unit of formula (OCH 2 CH 2 ) p , wherein p is an integer from 0 to about 1000, or combination thereof.
  • R 1 , R 2 , and R 3 can be respectively a chain of atoms selected from C, N, O, S, Si, and P which covalently connects the cell-surface binding molecule and/or the conjugated drug.
  • the atoms used in forming the bridge linker may be combined in all chemically relevant ways, such as forming alkylene, alkenylene, and alkynylene, ethers, polyoxyalkylene, esters, amines, imines, polyamines, hydrazines, hydrazones, amides, ureas, semicarbazides, carbazides, alkoxyamines, alkoxylamines, urethanes, amino acids, acyloxylamines, hydroxamic acids, and many others.
  • the atoms forming the linker (L) may be either saturated or unsaturated, or may be radicals, or may be cyclized upon each other to form divalent cyclic structures, including cyclo alkanes, cyclic ethers, cyclic amines, arylenes, heteroarylenes, and the like in the linker.
  • Examples of the functional groups, Z 1 and Z 2 which enable linkage of a cytotoxic drug, include groups that enable linkage via a disulfide, thioether, thioester, peptide, hydrazone, ester, carbamate, carbonate, alkoxime or an amide bond.
  • Such functional groups include, but are not limited to, thiol, disulfide, amino, carboxy, aldehydes, ketone, maleimido, haloacetyl, hydrazines, alkoxyamino, and/or hydroxy.
  • Examples of the functional groups, Z 1 and Z 2 , that enable reaction with the terminal of amine of a drug/ cytotoxic agent can be, but not limited to, N-hydroxysuccinimide esters, p-nitrophenyl esters, dinitrophenyl esters, pentafluorophenyl esters, carboxylic acid chlorides or carboxylic acid anhydride;
  • Examples of thiol can be, as but not limited to, pyridyldisulfides, nitropyridyldisulfides, maleimides, haloacetates,
  • ketone or aldehyde can be, as but not limited to, amines, alkoxyamines, hydrazines, acyloxylamine, or hydrazide;
  • azide can be, as but not limited to, alkyne. Examples of these function groups are displayed below:
  • X 1 is F, CI, Br, I or Lv 3
  • X 2 is O, NH, N(R 1 ), or CH 2
  • R 5 and R 3 are H, R 1 , aromatic, heteroaromatic, or aromatic group wherein one or several H atoms are replaced independently by -R 1 , -halogen, -OR 1 , -SR 1 , -NR1R2, - NO 2 , -S(O)R 1 , - S(O) 2 R 1, or -COOR 1
  • Lv 3 is a leaving group selected from nitrophenol; N-hydroxysuc- cinimide (NHS); phenol; dinitrophenol; pentafluorophenol; tetrafluorophenol;
  • difluorophenol difluorophenol; monofluorophenol; pentachlorophenol; triflate; imidazole; dichlorophenol; tetrachlorophenol; 1-hydroxybenzotriazole; tosylate; mesylate; 2-ethyl-5- phenylisoxazolium-3 '-sulfonate, anhydrides formed its self, or formed with the other anhydride, e.g. acetyl anhydride, formyl anhydride; or an intermediate molecule generated with a condensation reagent for peptide coupling reactions, or for Mitsunobu reactions.
  • anhydrides formed its self, or formed with the other anhydride, e.g. acetyl anhydride, formyl anhydride; or an intermediate molecule generated with a condensation reagent for peptide coupling reactions, or for Mitsunobu reactions.
  • the key step of synthesis of the bridge linker containing 2,3-disubstituted succinic group, or 2-monosubstituted or 2,3-disubstituted fumaric group, or 2-monosubstituted or 2,3-disubstituted maleic group is the condensation of the 2,3-disubstituted succinic acid, or 2-monosubstituted or 2,3-disubstituted fumaric acid, or 2-monosubstituted or 2,3- disubstituted maleic acid, or its acid derivatives, with the other components containing an amine (1° or 2° amines), alcohol, or thiol on their terminal, as shown in the following scheme (la):
  • X is X 1 or X 2 described in Formula (I) as NH, N(R 3 ), O, or S; R is R 1 and/or R 2 that described in Formula (I); R 3 is the same defined in Formula (I).
  • Lvi and Lv 2 are the same or independently OH; F; CI; Br; I; nitrophenol; N-hydroxy- succinimide (NHS); phenol; dinitrophenol; pentafluorophenol; tetrafluorophenol;
  • difluorophenol difluorophenol; monofluorophenol; pentachlorophenol; triflate; imidazole; dichlorophenol; tetrachlorophenol; 1-hydroxybenzotriazole; tosylate; mesylate; 2-ethyl-5- phenylisoxazolium-3 '-sulfonate, anhydrides formed its self, or formed with the other anhydride, e.g. acetyl anhydride, formyl anhydride; or an intermediate molecule generated with a condensation reagent for peptide coupling reactions, or for Mitsunobu reactions, e.g.
  • condensation reagents are: EDC (N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide), DCC (Dicyclohexyl-carbodiimide), ⁇ , ⁇ '-Diisopropylcarbodiimide (DIC), N-Cyclohexyl- N'-(2-morpholino-ethyl)carbodiimide metho-p-toluenesulfonate (CMC,or CME-CDI), 1,1 '- Carbonyldiimi-dazole (CDI),TBTU (O-(Benzotriazol-l-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate), N,N,N',N'-Tetramethyl-O-(lH-benzotriazol-l-yl)uronium
  • HBTU hexafluorophosphate
  • BOP Benzotriazol- l-yloxytris(dimethylamino)phosphonium hexafluorophosphate
  • BOP Benzotriazol- l-yloxytripyrrolidinophosphonium
  • hexafluorophosphate PyBOP
  • Diethyl cyanophosphonate DEPC
  • Chloro- ⁇ , ⁇ , ⁇ ', ⁇ '- tetramethylformamidinium hexafluorophosphate l-[Bis(dimethylamino)methylene]-lH- l,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (HATU), l-[(Dimethylami- no)(morpholino) methylene]- lH-[l,2,3]triazolo[4,5-b]pyridine-l-ium 3-oxide hexafluorophosphate (HDMA), 2-Chloro-l,3-dimethylimidazolidinium hexafluorophosphate (CIP), Chlorotripyrrolidinophosphonium hexafluorophosphate (PyCloP), Fluoro-N,N,N',N'-bis
  • Oxido-2-pyridyl)-N,N,N',N'-tetramethylthiuronium tetrafluoroborate O-[(Ethoxycarbonyl) cyano-methylenamino]-N,N,N',N'-tetramethyluronium hexafluorophosphate (HOTU), (1- Cyano-2-ethoxy-2-oxoethylidenaminooxy) dimethylamino-morpholino-carbenium hexafluorophosphate(COMU), O-(Benzotriazol-l-yl)-N,N,N',N'-bis(tetramethylene) uronium hexafluorophosphate (HBPyU), N-Benzyl-N'-cyclohexylcarbodiimide (with, or without polymer-bound), Dipyrrolidino(N-succinimidyl-oxy)carbenium hexafluorophosphat
  • DMTMM N,N,N',N'-Tetramethyl-O-(N-succinimidyl)uronium tetrafluoroborate (TSTU), O- (3,4-Dihydro-4-oxo-l,2,3-benzotriazin-3-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate (TDBTU), l, -(Azodicarbonyl)dipiperidine (ADD), Di-(4-chlorobenzyl) azodicar- boxylate (DCAD), Di-tert-butyl azodicarboxylate (DBAD), Diisopropyl azodicarboxylate (DIAD), Diethyl azodicarboxylate (DEAD).
  • ADD Di-(4-chlorobenzyl) azodicar- boxylate
  • DAD Di-tert-butyl azodicarboxylate
  • DIAD Diis
  • bridge substituents of 2,3-disubstituted succinic group, or 2- monosubstituted or 2,3-disubstituted fumaric group, or 2-monosubstituted or 2,3- disubstituted maleic group can be condensated with linker components containing function groups capable to react to drugs of desired conjugation.
  • Cb is a cell-binding agent
  • L is linker containing succinic, fumaric or maleic group
  • Drug 1 and Drug 2 are a drug molecule
  • n is an integer from 1 to 30
  • S (sulfur) elements from Cb bridgely link to L which covalently connects two or more drugs (per bridge linker L).
  • the bridge linker L may be composed of one or more linker components.
  • exemplary linker components include 6-maleimidocaproyl ("MC"), maleimidopropanoyl (“MP”), valine-citrulline (“val-cit” or “vc”), alanine-phenylalanine (“ala-phe” or “af”), p- aminobenzyloxycarbonyl (“PAB”), 4-thiopentanoate (“SPP”), 4-(N-maleimidomethyl)- cyclohexane- 1 carboxylate (“MCC”), (4-acetyl)aminobenzoate (“SIAB”), 4-thio-butyrate (SPDB), 4-thio-2-hydroxysulfonyl-butyrate (2-Sulfo-SPDB), ethyleneoxy -CH 2 CH 2 O- as one or more repeating units (“EO” or “PEO”). Additional linker components are known in the art and some are described herein.
  • the conjugates have the following Formula ( ⁇ ):
  • Cb represents a cell-binding agent, preferably an antibody, which conjugates to Drug 1 and Drug 2 via a pair of sulfur atoms (thiols).
  • the conjugatable thiol groups can generally be generated from dithiothreitol (DTT), dithioerythritol (DTE), L-glutathione (GSH) and tris (2-carboxyethyl) phosphine (TCEP), or/and beta mercaptoethanol ( ⁇ - ⁇ , 2-ME) reduction of pairs of disulfide bonds on the surface of cell-binding molecule.
  • Drug 1 and Drug 2 represent the same or different cytotoxic agents, linked to the cell- binding agent via the bridge linker through an alkyl, alkylene, alkenylene, alkynylene, ether, polyoxyalkylene, ester, amine, imine, polyamine, hydrazine, hydrazone, amide, urea, semicarbazide, carbazide, alkoxyamine, urethanes, amino acid, peptide, acyloxylamine, hydroxamic acid, disulfide, thioether, thioester, carbamate, carbonate, heterocyclic ring, heteroalkyl, heteroaromatic, or alkoxime bond, or combination thereof.
  • Drug 1 and Drug 2 can be any of many small molecule drugs, including, but not limited to, tubulysins, calicheamicins, auristatins,
  • benzodiazepine dimers e.g., dimmers of pyrrolobenzodiazepine (PBD) or tomaymycin
  • indolinobenzodiazepines imidazobenzothiadiazepines, or
  • the cell-binding agent can be first modified with the bridge linkers of the present invention through reduction of disulfide bonds of the cell- binding molecule.
  • the yielded a pair of free thiols can react to the bridge linker of Formula (I) at pH 5-9 aqueous media with or without addition of 0-30% of water mixable (miscible) organic solvents, such as DMA, DMF, ethanol, methanol, acetone, acetonitrile, THF, isopropanol, dioxane, propylene glycol, or ethylene diol, to introduce the reactive groups of Z 1 and Z 2 containing disulfide, maleimido, haloacetyl, azide, 1-yne, ketone, aldehyde, alkoxyamino, or hydrazide groups.
  • a reactive group of a cytotoxic agent reacts to the modified cell-binding molecule accordingly.
  • synthesis of the cell-binding agent-drug conjugates linked via disulfide bonds is achieved by a disulfide exchange between the disulfide bond in the modified cell-binding agent and a drug containing a free thiol group.
  • Synthesis of the cell-binding agent-drug conjugates linked via thioether is achieved by reaction of the maleimido or haloacetyl or ethylsulfonyl modified cell-binding agent and a drug containing a free thiol group.
  • Synthesis of conjugates bearing an acid labile hydrazone can be achieved by reaction of a carbonyl group with the hydrazide moiety in the linker, by methods known in the art (see, for example, P. Hamann et al., Cancer Res. 53, 3336-334, 1993; B. Laguzza et al., J. Med. Chem., 32; 548-555, 1959; P. Trail et al., Cancer Res., 57; 100-105, 1997).
  • Synthesis of conjugates bearing triazole linkage can be achieved by reaction of a 1-yne group of the drug with the azido moiety in the linker, through the click chemistry (Huisgen cycloaddition) (Lutz, J-F. et al, 2008, Adv.
  • the drug can react with the bridge linkers of the present invention that have conjugated to a cell-binding molecule to give a modified cell-binding molecule linker of Formula (III) bearing functionalities.
  • a thiol-containing drug can be reached with the modified cell-binding molecule bridge linker of Formula (III) bearing a maleimdo, or a haloacetyl, or an ethylsulfonyl substituent at pH 5.5-9.0 in aqueous buffer to give a cell-binding molecule-drug conjugate via a thioether linkage.
  • a thiol-containing drug can undergo disulfide exchange with a modified bridge linker of Formula (III) bear- ing a pyridyldithio moiety to give a conjugate a disulfide bond linkage.
  • a drug bearing a hydroxyl group or a thiol group can be reacted with a modified bridge linker of Formula (III) bearing a halogen, particularly the alpha halide of carboxylates, in the presence of a mild base, e.g. pH 8.0-9.5, to give a modified drug bearing an ether or thiol ether link.
  • a hydroxyl group containing drug can be condensed with a bridge cross linker of Formula (I) bearing a carboxyl group, in the presence of a dehydrating agent, such as EDC or DCC, to give ester linkage, then the subject drug modified bridge linker undergoes the conjugation with a cell-binding molecule.
  • a dehydrating agent such as EDC or DCC
  • a drug containing an amino group can condensate with a carboxyl ester of NHS, imidazole, nitrophenol; N-hydroxysuccinimide (NHS); phenol; dinitrophenol; pentafluorophenol; tetrafluorophenol; difluorophenol; monofluorophenol; pentachlorophenol; triflate; imidazole; dichlorophenol; tetrachlorophenol; 1- hydroxybenzotriazole; tosylate; mesylate; 2-ethyl-5-phenylisoxazolium-3 '-sulfonate on the cell-binding molecule-bridge linker of Formula (III) to give a conjugate via amide bond linkage.
  • NHS N-hydroxysuccinimide
  • the conjugate may be purified by standard biochemical means, such as gel filtration on a Sephadex G25 or Sephacryl S300 column, adsorption chromatography, and ion exchange or by dialysis.
  • a small molecule as a cell-binding agent e.g. folic acid, melanocyte stimulating hormone, EGF etc
  • a small molecular drugs can be purified by chromatography such as by HPLC, medium pressure column chromatography or ion exchange chromatography.
  • the cell-binding agent modified by reaction with linkers of the present invention are preferably represented by the Formula (III)
  • Cb, Z 1 , Z 2 , n, R 1 , R 2 , Xi, and X 2 are defined the same as in
  • Z 1 and Z 2 are a disulfide substituent, maleimido, haloacetyl, alkoxyamine, azido, ketone, aldehyde, hydrazine, alkyne, an N-hydroxysuccinimide ester, or a carboxyl ester formed with phenol; dinitrophenol; pentafluorophenol; tetrafluoro- phenol; difluorophenol; monofluorophenol; pentachlorophenol; triflate; imidazole;
  • the modified cell-binding agent can be prepared via a reaction of the cell- binding agent with the bridge linkers of Formula (I) as described in Formula (II) above.
  • a small percentage of organic co- solvent may be required to add to the reaction mixture, as well in the solution after the reaction to maintain solubility of the Formula (III) in aqueous solution.
  • the cross-linking reagent (bridge linker) of Formula (I) can be first dissolved in a polar organic solvent that is miscible with water, for example different alcohols, such as methanol, ethanol, and propanol, acetone, acetonitrile, tetrahydrofuran (THF), 1,4-dioxane, dimethyl formamide (DMF), dimethyl acetamide (DMA), or dimethylsulfoxide (DMSO) at a high concentration, for example 1-500 mM.
  • a polar organic solvent that is miscible with water
  • a polar organic solvent that is miscible with water
  • alcohols such as methanol, ethanol, and propanol
  • acetone acetonitrile
  • THF tetrahydrofuran
  • DMF dimethyl formamide
  • DMA dimethyl acetamide
  • DMSO dimethylsulfoxide
  • the cell-binding molecule such as antibody dissolved in an aqueous buffer pH 5-9.5, preferably pH 6-8.5, at 1-35 mg/ml concentration was treated with 1-20 equivalent of TCEP or DTT for 20 min to 12 hour. After the reduction, DTT can be removed by SEC chromatographic purification. TCEP can be optionally removed by SEC chromatography too, or staying in the reaction mixture for the next step reaction without purification.
  • the reduction of antibodies or the other cell-binding agents with TCEP can be performed with a bridge linker of Formula (I), for which the cross-linking conjugation for the cell-binding molecules can be achieved simultaneously along with the TCEP reduction.
  • aqueous solutions for the modification of cell-binding agents are buffered between pH 6 and 9, preferably between 6.5 and 7.5 and can contain any non-nucleophilic buffer salts useful for these pH ranges.
  • Typical buffers include phosphate, triethanolamine HC1, HEPES, and MOPS buffers, which can contain additional components, such as cyclodextrins, sucrose and salts, for examples, NaCl and KC1.
  • the progress of the reaction can be monitored by measuring the decrease in the absorption at 254 nm, or increase in the absorption at 280 nm, or the other appropriate wavelength.
  • isolation of the modified cell- binding agent can be performed in a routine way, using for example gel filtration chromatography, or adsorptive chromatography.
  • the extent of modification can be assessed by measuring the absorbance of the nitropyridine thione, dinitropyridine dithione, pyridine thione, carboxamidopyridine dithione and dicarboxamidopyridine dithione group released via UV spectra.
  • the modification or conjugation reaction can be monitored by LC-MS, preferably by UPLC-QTOF mass spectrometry, or Capil- lary electrophoresis-mass spectrometry (CE-MS).
  • the bridge cross-linkers described herein have diverse functional groups that can react with any drugs, preferably cytotoxic agents that possess a suitable substituent.
  • the modified cell-binding molecules bearing an amino or hydroxyl substituent can react with drugs bearing an
  • the modified cell-binding molecules bearing a thiol substituent can react with drugs bearing a maleimido or haloacetyl group.
  • the modified cell-binding molecules bearing a carbonyl (ketone or aldehyde) substituent can react with drugs bearing a hydrazide or an alkoxyamine.
  • cytotoxic drugs modified by reaction with cross-linkers of the present invention are preferably represented by the Formula (IV):
  • the modified drugs can be prepared via reaction of the drug with the linkers of the Formula (I) to give a modified drug of Formula (IV) bearing functionality of an 2,3- disubstituted succinic group, or 2-monosubstituted or 2,3-disubstituted fumaric group, or 2-monosubstituted or 2,3-disubstituted maleic group.
  • the Drug 1 or Drug 2 may be synthesized to connect to R 1 , or R 2 in a piece of components via the linkage of thioether, thioester or disulfide bond first.
  • R 1 -Drug 1 or R 2 -Drug 2 component is assembled to 2,3-disubstituted succinic acid, or 2-monosubstituted or 2,3-disubstituted fumaric acid, or 2-monosubstituted or 2,3-disubstituted maleic acid to form the bridge linker modified drugs of Formula (IV).
  • a thiol-containing drug can be reacted with the linker of components R 1 or R 2 bearing a maleimdo substituent at neutral pH in aqueous buffer to give a R 1 -Drug 1 or R 2 -Drug 2 compartment bearing thioether linkage, and following by condensation with either 2,3-disubstituted succinic acid, or 2-monosubstituted or 2,3- disubstituted fumaric acid, or 2-monosubstituted or 2,3-disubstituted maleic acid to give a modified drug of Formula (IV) bearing thioether linkage.
  • a drug bearing a hydroxyl group can be reacted with a linker component R 1 or R 2 bearing a halogen, or a tosylate, or a mesylate, in the presence of a mild base, to give a R 1 -Drug 1 or R 2 -Drug 2 compartment bearing ether linkage, and following by condensation with 2,3-disubstituted succinic acid, or 2-monosubstituted or 2,3-disubstituted fumaric acid, or 2-monosubstituted or 2,3- disubstituted maleic acid to give a modified drug of Formula (IV) bearing thioether linkage.
  • a hydroxyl group containing drug can be condensed with a linker of Formula (I) bearing a carboxyl group, in the presence of a dehydrating agent, such as EDC or dicyclohexylcarbodiimide (DCC), to give a modified drug of Formula (IV) via ester linkage.
  • a dehydrating agent such as EDC or dicyclohexylcarbodiimide (DCC)
  • a drug bearing a thiol group can also react the linker of components R 1 or R 2 bearing a maleimido or a vinylsulfonyl, or a haloacetyl group, give a R 1 -Drug 1 or R 2 -Drug 2 compartment bearing thioether linkage, and following by condensation with a compartment of 2,3-disubstituted succinic acid, or 2-monosubstituted or 2,3-disubstituted fumaric acid, or 2-monosubstituted or 2,3-disubstituted maleic acid to give a modified drug of Formula (IV) bearing thioether linkage.
  • An amino group containing drug can similarly undergo condensation with a carboxyl group on the bridge linker of Formula (I) to give a modified drug of Formula (IV) bearing amide bonds.
  • the modified drug can be purified by standard methods such as column chromatography over silica gel or alumina, crystallization, preparatory thin layer chromatography, ion exchange chromatography, or HPLC.
  • the cell-binding molecule that comprises the conjugates and the modified cell-binding agents of the present invention may be of any kind presently known, or that become known, molecule that binds to, complexes with, or reacts with a moiety of a cell population sought to be therapeutically or otherwise biologically modified.
  • the cell binding agents include, but are not limited to, large molecular weight proteins such as, for example, full-length antibodies (polyclonal antibodies, monoclonal antibodies, dimers, multimers, multispecific antibodies (e.g., bispecific antibodies); single chain antibodies; fragments of antibodies such as Fab, Fab', F(ab') 2 , F v [Parham, J. Immunol. 131, 2895-2902 (1983)], fragments produced by a Fab expression library, anti-idiotypic
  • anti-Id antibodies antibodies, CDR's, diabody, triabody, tetrabody, miniantibody, small immune proteins (SIP), and epitope-binding fragments of any of the above which immuno- specifically bind to cancer cell antigens, viral antigens, microbial antigens or a protein generated by the immune system that is capable of recognizing, binding to a specific antigen or exhibiting the desired biological activity (Miller et al (2003) J. of Immunology
  • interferons such as type I, II, III
  • peptides such as lymphokines such as IL-2, IL-3, IL-4, IL-5, IL-6, IL-10, GM-CSF, interferon-gamma (IFN- ⁇ ); hormones such as insulin, TRH (thyrotropin releasing hormones), MSH (melanocyte- stimulating hormone), steroid hormones, such as androgens and estrogens, melanocyte- stimulating hormone (MSH); growth factors and colony-stimulating factors such as epidermal growth factors
  • EGF granulocyte-macrophage colony-stimulating factor
  • TGF transforming growth factors
  • IGF-I, IGF-II insulin and insulin like growth factors
  • GEF vaccinia growth factors
  • FGFs fibroblast growth factors
  • platelet-derived growth factors such as interleukin-2 (IL-2), interleukin-6 (IL-6), leukemia inhibitory factors, granulocyte- macrophage colony- stimulating factor (GM-CSF); vitamins, such as folate; apoproteins and glycoproteins, such as transferrin [O'Keefe
  • a monoclonal antibody is preferred as a cell-surface binding agent if an appropriate one is available.
  • the antibody may be murine, human, humanized, chimeric, or derived from other species.
  • a monoclonal antibody is typically made by fusing myeloma cells with the spleen cells from a mouse that has been immunized with the desired antigen (Kohler, G.; Milstein, C.
  • monoclonal antibodies are produced by immunizing mice, rats, hamsters or any other mammal with the antigen of interest such as the intact target cell, antigens isolated from the target cell, whole virus, attenuated whole virus, and viral proteins.
  • Splenocytes are typically fused with myeloma cells using polyethylene glycol (PEG) 6000.
  • Fused hybrids are selected by their sensitivity to HAT (hypoxanthine-aminopterin-thymine).
  • Hybridomas producing a monoclonal antibody useful in practicing this invention are identified by their ability to immunoreact specified receptors or inhibit receptor activity on target cells.
  • a monoclonal antibody used in the present invention can be produced by initiating a monoclonal hybridoma culture comprising a nutrient medium containing a hybridoma that secretes antibody molecules of the appropriate antigen specificity.
  • the culture is maintained under conditions and for a time period sufficient for the hybridoma to secrete the antibody molecules into the medium.
  • the antibody-containing medium is then collected.
  • the antibody molecules can then be further isolated by well-known techniques, such as using protein-A affinity chromatography; anion, cation, hydrophobic, or size exclusive chromatographies (particularly by affinity for the specific antigen after protein A, and sizing column chromatography); centrifugation, differential solubility, or by any other standard technique for the purification of proteins.
  • An exemplary synthetic medium is Dulbecco's minimal essential medium (DMEM; Dulbecco et al., Virol. 8, 396 (1959)) supplemented with 4.5 gm/1 glucose, 0-20 mM glutamine, 0-20% fetal calf serum, several ppm amount of heavy metals, such as Cu, Mn, Fe, or Zn, etc, or/and the heavy metals added in their salt forms, and with an anti-foaming agent, such as polyoxyethylene- polyoxypropylene block copolymer.
  • DMEM Dulbecco's minimal essential medium
  • DMEM Dulbecco's minimal essential medium
  • heavy metals such as Cu, Mn, Fe, or Zn, etc
  • an anti-foaming agent such as polyoxyethylene- polyoxypropylene block copolymer.
  • antibody-producing cell lines can also be created by techniques other than fusion, such as direct transformation of B lymphocytes with oncogenic DNA, or transfec- tion with an oncovirus, such as Epstein-Barr virus (EBV, also called human herpesvirus 4
  • EBV Epstein-Barr virus
  • HHV-4 Kaposi's sarcoma-associated herpesvirus
  • KSHV Kaposi's sarcoma-associated herpesvirus
  • a monoclonal antibody may also be produced via an anti-receptor peptide or peptides containing the carboxyl terminal as described well-known in the art. See Niman et al., Proc. Natl. Acad. Sci. USA, 80: 4949-4953 (1983); Geysen et al., Proc. Natl. Acad. Sci.
  • the anti-receptor peptide or a peptide analog is used either alone or conjugated to an immunogenic carrier, as the immunogen for producing anti-receptor peptide monoclonal antibodies.
  • phage display technology which can be used to select a range of human antibodies binding specifically to the antigen using methods of affinity enrichment. Phage display has been thoroughly described in the literature and the construction and screening of phage display libraries are well known in the art, see, e.g.,
  • Monoclonal antibodies derived by hybridoma technique from another species than human, such as mouse, can be humanized to avoid human anti-mouse antibodies when infused into humans.
  • humanization of antibodies are complementarity-determining region grafting and resurfacing. These methods have been extensively described, see e.g. U.S. Pat. Nos. 5,859,205 and 6,797,492; Liu et al, Immunol Rev. 222:9-27 (2008); Almagro et al, Front Biosci. 13: 1619-33 (2008); Lazar et al, Mol Immunol. 44(8): 1986-98 (2007); Li et al, Proc. Natl. Acad. Sci. U S A. 103(10):3557-62 (2006) each incorporated herein by reference.
  • Fully human antibodies can also be prepared by immunizing transgenic mice, rabbits, monkeys, or other mammals, carrying large portions of the human immunoglobulin heavy and light chains, with an immunogen.
  • mice examples include the Xenomouse. (Abgenix/Amgen), the HuMAb-Mouse (Medarex/BMS), the VelociMouse (Regeneron), see also U.S. Pat. No. 6,596,541 , 6,207,418, No. 6,150,584, No. 6,111,166, No. 6,075,181, No. 5,922,545, Nos. 5,661,016, 5,545,806, 5,436,149 and 5,569,825.
  • murine variable regions and human constant regions can also be fused to construct called "chimeric antibodies" that are considerably less immunogenic in man than murine mAbs (Kipriyanov et al, Molarcomas).
  • Antibodies immuno specific for a malignant cell antigen can also be obtained commercially or produced by any method known to one of skill in the art such as, e.g., chemical synthesis or recombinant expression techniques.
  • the nucleotide sequence encoding antibodies immuno specific for a malignant cell antigen can be obtained commercially, e.g., from the GenBank database or a database like it, the literature publications, or by routine cloning and sequencing.
  • a peptide or protein that bind/block/target or in some other way interact with the epitopes or corresponding receptors on a targeted cell can be used as a binding molecule.
  • These peptides or proteins could be any random peptide or proteins that have an affinity for the epitopes or corresponding receptors and they don't necessarily have to be of the immunoglobulin family.
  • These peptides can be isolated by similar techniques as for phage display antibodies (Szardenings, J Recept Signal Transduct Res. 2003; 23(4):307-49). The use of peptides from such random peptide libraries can be similar to antibodies and antibody fragments.
  • binding molecules of peptides or proteins may be conjugated on or linked to a large molecules or materials, such as, but is not limited, an albumin, a polymer, a liposome, a nano particle, a dendrimer, as long as such attachment permits the peptide or protein to retain its antigen binding specificity.
  • a large molecules or materials such as, but is not limited, an albumin, a polymer, a liposome, a nano particle, a dendrimer, as long as such attachment permits the peptide or protein to retain its antigen binding specificity.
  • antibodies used for conjugation of drugs via the bridge linkers of this prevention for treating cancer, autoimmune disease, and/or infectious disease include, but are not limited to, 3F8 (anti-GD2), Abagovomab (anti CA-125), Abciximab (anti CD41
  • Adalimumab anti-TNF-a
  • Adecatumumab anti-EpCAM, CD326)
  • Afelimomab anti-TNF-a
  • Afutuzumab anti-CD20
  • Alacizumab pegol anti-VEGFR2
  • ALD518 anti-IL-6
  • Alemtuzumab Campath, MabCampath, anti- CD52
  • Altumomab anti-CEA
  • Anatumomab anti-TAG-72
  • Anrukinzumab IMA-638, anti-IL-13
  • Apolizumab anti-HLA-DR
  • Arcitumomab anti-CEA
  • Aselizumab anti-L-selectin (CD62L)
  • Atlizumab tocilizumab, Actemra, RoActemra, anti-IL-6 receptor
  • Atorolimumab anti-Rhesus factor
  • Bapineuzumab anti-beta amyloid
  • Basiliximab Simulect, antiCD25 (a chain of IL-2 receptor)
  • Bavituximab anti-phosphatidylserine
  • Bectumomab LymphoScan, anti-CD22
  • Belimumab Benlysta, LymphoStat-B, anti-
  • Besilesomab (Scintimun, anti-CEA-related antigen), Bevacizumab (Avastin, anti-VEGF- A), Biciromab (FibriScint, anti-fibrin II beta chain), Bivatuzumab (anti-CD44 v6), Blinatumomab (BiTE, anti-CD19), Brentuximab (cACIO, anti-CD30 TNFRSF8),
  • Briakinumab (anti-IL-12, IL-23) Canakinumab (Ilaris, anti-IL-1), Cantuzumab (C242, anti-IL-12, IL-23) Canakinumab (Ilaris, anti-IL-1), Cantuzumab (C242, anti-IL-12, IL-23) Canakinumab (Ilaris, anti-IL-1), Cantuzumab (C242, anti-
  • CanAg Capromab, Catumaxomab (Removab, anti-EpCAM, anti-CD3), CC49 (anti-TAG- 72), Cedelizumab (anti-CD4), Certolizumab pegol (Cimzia anti-TNF-a), Cetuximab (Er- bitux, IMC-C225, anti-EGFR), Citatuzumab collectingox (anti-EpCAM), Cixutumumab (anti- IGF-1), Clenoliximab (anti-CD4), Clivatuzumab (anti-MUCl), Conatumumab (anti- TRAIL-R2), CR6261 (anti-Influenza A hemagglutinin), Dacetuzumab (anti-CD40),
  • Daclizumab (Zenapax, anti-CD25 (a chain of IL-2 receptor)), Daratumumab (anti-CD38 (cyclic ADP ribose hydrolase), Denosumab (Prolia, anti-RANKL), Detumomab (anti-B- lymphoma cell), Dorlimomab, Dorlixizumab, Ecromeximab (anti-GD3 ganglioside), Eculizumab (Soliris, anti-C5), Edobacomab (anti-endotoxin), Edrecolomab (Panorex, MAbl7-lA, anti-EpCAM), Efalizumab (Raptiva, anti-LFA-1 (CD1 la), Efungumab
  • Enlimomab pegol (anti-IC AM- 1 (CD54)), Epitumomab (anti-episialin), Epratuzumab (anti-CD22), Erlizumab (anti-ITGB2 (CD 18)), Ertumaxomab (Rexomun, anti-HER2/neu, CD3), Etaracizumab (Abegrin, anti-integrin ⁇ ⁇ ⁇ 3 ), Exbivirumab ( anti-hepatitis B surface antigen), Fanolesomab (NeutroSpec, anti-CD15), Faralimomab (anti-interferon receptor),
  • Farletuzumab (anti-folate receptor 1), Felvizumab (anti-respiratory syncytial virus), Fezakinumab (anti-IL-22), Figitumumab (anti-IGF-1 receptor), Fontolizumab (anti-IFN- ⁇ ), Foravirumab (anti-rabies virus glycoprotein), Fresolimumab (anti-TGF- ⁇ ), Galiximab (anti-CD80), Gantenerumab (anti- beta amyloid), Gavilimomab (anti-CD 147 (basigin)), Gemtuzumab (anti-CD33), Girentuximab (anti-carbonic anhydrase 9), Glembatumumab
  • IgE receptor Mapatumumab (anti-TRAIL-Rl), Maslimomab (anti- T-cell receptor), Matuzumab (anti-EGFR), Mepolizumab (Bosatria, anti-IL-5), Metelimumab (anti-TGF beta 1), Milatuzumab (anti-CD74), Minretumomab (anti-TAG-72), Mitumomab (BEC-2, anti-GD3 ganglioside), Morolimumab (anti-Rhesus factor), Motavizumab (Numax, anti- respiratory syncytial virus), Muromonab-CD3 (Orthoclone OKT3, anti-CD3), Nacolomab
  • Oregovomab (OvaRex, anti-CA-125), Otelixizumab (anti-CD3), Pagibaximab (anti- lipoteichoic acid), Palivizumab (Synagis, Abbosynagis, anti-respiratory syncytial virus), Panitumumab (Vectibix, ABX-EGF, anti-EGFR), Panobacumab (anti- Pseudomonas aeruginosa), Pascolizumab (anti-IL-4), Pemtumomab (Theragyn, anti-MUCl), Pertuzumab (Omnitarg, 2C4, anti-HER2/neu), Pexelizumab (anti-C5), Pintumomab (anti- adenocarcinoma antigen), Priliximab (anti-CD4), Pritumumab (anti-vimentin), PRO 140 (anti-CCR5), Ra
  • Solanezumab anti-beta amyloid
  • Sonepcizumab anti-sphingosine-1 -phosphate
  • Sontuzumab (anti-episialin), Stamulumab (anti-myo statin), Sulesomab (LeukoScan, (anti- NCA-90 (granulocyte antigen), Tacatuzumab (anti-alpha-fetoprotein), Tadocizumab (anti- integrin ⁇ 3 ⁇ 4 ⁇ 3 ), Talizumab (anti-IgE), Tanezumab (anti-NGF), Taplitumomab (anti-CD 19), Tefibazumab (Aurexis, (anti-clumping factor A), Telimomab, Tenatumomab (anti-tenascin C), Teneliximab (anti-CD40), Teplizumab (anti-CD3), TGN1412 (anti-CD28),
  • Ticilimumab (Tremelimumab, (anti-CTLA-4), Tigatuzumab (anti-TRAIL-R2), TNX-650 (anti-IL-13), Tocilizumab (Atlizumab, Actemra, RoActemra, (anti-IL-6 receptor),
  • Toralizumab anti-CD154 (CD40L)
  • Tositumomab anti-CD20
  • Trastuzumab trastuzumab
  • Vedolizumab (anti-integrin ⁇ 4 ⁇ 7 ), Veltuzumab (anti-CD20), Vepalimomab (anti-AOC3 (VAP-1), Visilizumab (Nuvion, anti-CD3), Vitaxin (anti-vascular integrin avb3),
  • Volociximab anti-integrin ⁇ 5 ⁇ 1
  • Votumumab (HumaSPECT, anti-tumor antigen
  • CTAA16.88 Zalutumumab (HuMax-EGFr, (anti-EGFR), Zanolimumab (HuMax-CD4, anti-CD4), Ziralimumab (anti-CD 147 (basigin)), Zolimomab (anti-CD5), Etanercept (Enbrel®), Alefacept (Amevive®), Abatacept (Orencia®), Rilonacept (Arcalyst), 14F7 [anti-IRP-2 (Iron Regulatory Protein 2)], 14G2a (anti-GD2 ganglioside, from Nat. Cancer
  • J591 anti-PSMA, Weill Cornell Medical School for prostate cancers
  • 225.28S anti-HMW-MAA (High molecular weight-melanoma- associated antigen)
  • Sorin Radiofarmaci S.R.L. Med, Italy
  • COL-1 anti- CEACAM3, CGMl, from Nat. Cancer Inst. USA for colorectal and gastric cancers
  • CYT- 356 Oncoltad®, for prostate cancers
  • HNK20 OraVax Inc.
  • ImmuRAIT from Immunomedics for NHL
  • Lym-1 anti-HLA-DRlO, Peregrine Pharm. for Cancers
  • MAK-195F anti-TNF (tumor necrosis factor; TNFA, TNF-alpha; TNFSF2), from Abbott / Knoll for Sepsis toxic shock
  • MEDI-500 [T10B9, anti-CD3, TRaP (T cell receptor alpha/beta), complex, from Medlmmune Inc for Graft-versus-host disease]
  • RING SCAN anti-TAG 72 (tumour associated glycoprotein 72), from Neoprobe
  • antibodies as cell binding molecules/ligands include, but are not limited to, are antibodies against the following antigens: Aminopeptidase N (CD13), Annexin Al, B7-H3 (CD276, various cancers), CA125 (ovarian), CA15-3 (carcinomas), CA19-9 (carcinomas), L6 (carcinomas), Lewis Y (carcinomas), Lewis X (carcinomas), alpha fetoprotein (carci- nomas), CA242 (colorectal), placental alkaline phosphatase (carcinomas), prostate specific antigen (prostate), prostatic acid phosphatase (prostate), epidermal growth factor (carcinomas), CD2 (Hodgkin's disease, NHL lymphoma, multiple myeloma), CD3 epsilon (T cell lymphoma, lung, breast, gastric, ovarian cancers, autoimmune diseases, malignant ascites), CD 19 (B cell malignancies), CD20 (non-Hodgkin'
  • Endoglin CD 105, solid tumors
  • EPCAM epidermal cell adhesion molecule
  • bladder head, neck, colon, NHL prostate, and ovarian cancers
  • ERBB2 Epidermal Growth Factor Receptor 2; lung, breast, prostate cancers
  • FCGR1 autoimmune diseases
  • FOLR farnesoid receptor
  • GD2 ganglioside cancers
  • G-28 a cell surface antigen glyvolipid, melanoma
  • GD3 idiotype cancers
  • Heat shock proteins cancers
  • HLA-DR10 (NHL), HLA-DRB (NHL, B cell leukemia), human chorionic gonadotropin (carcinoma), IGF1R (insulin-like growth factor 1 receptor, solid tumors, blood cancers), IL-2 receptor (interleu- kin 2 receptor, T-cell leukemia and lymphomas), IL-6R (interleukin 6 receptor, multiple myeloma, RA, Castleman's disease, IL6 dependent tumors), Integrins ( ⁇ 3, ⁇ 5 ⁇ 1, ⁇ 6 ⁇ 4, ⁇ 11 ⁇ 3, ⁇ 5 ⁇ 5, ⁇ 5, for various cancers), MAGE-1 (carcinomas), MAGE-2 (carcinomas), MAGE-3 (carcinomas), MAGE 4 (carcinomas), anti-transferrin receptor (carcinomas), p97 (melanoma), MS4A1 (membrane-spanning 4-domains subfamily A member 1, Non- Ho
  • TRAIL-R1 Tumor necrosis apoprosis Inducing ligand Receptor 1, lymphoma, NHL, colorectal, lung cancers
  • VCAM-1 CD 106, Melanoma
  • VEGF VEGF-A
  • VEGF-2 CD309
  • Some other tumor associated antigens recognized by antibodies have been reviewed (Gerber, et al, mAbs 1:3, 247-253 (2009); Novellino et al, Cancer Immunol Immunother. 54(3), 187-207 (2005). Franke, et al, Cancer
  • the cell-binding agents can be any agents that are able to against tumor cells, virus infected cells, microorganism infected cells, parasite infected cells, autoimmune cells, activated cells, myeloid cells, activated T-cells, B cells, or mela- nocytes.
  • the cell binding agents can be any agent/molecule that is able to against any one of the following antigens or receptors: CD3, CD4, CD5, CD6, CD7, CD8, CD9, CD10, CDl la, CDl lb, CDl lc, CD12w, CD14, CD15, CD16, CDwl7, CD18, CD19, CD20, CD21, CD22, CD23, CD24, CD25, CD26, CD27, CD28, CD29, CD30, CD31, CD32, CD33, CD34, CD35, CD36, CD37, CD38, CD39, CD40, CD41, CD42, CD43, CD44, CD45, CD46, CD47, CD48, CD49b, CD49c, CD51, CD52, CD53, CD54,
  • Angiopoietin 2 Angiopoietin 3, Annexin Al, Anthrax toxin protective antigen, Anti- transferrin receptor, AOC3 (VAP-1), B7-H3, Bacillus anthracis anthrax, BAFF (B-cell activating factor), B-lymphoma cell, bcr-abl, Bombesin, BORIS, C5, C242 antigen, CA125
  • Clumping factor A CRIPTO, FCSF1R (Colony stimulating factor 1 receptor, CD115), CSF2 (colony stimulating factor 2, Granulocyte-macrophage colony- stimulating factor (GM-CSF)), CTLA4 (cytotoxic T-lymphocyte-associated protein 4), CTAA16.88 tumor antigen, CXCR4 (CD 184), C-X-C chemokine receptor type 4, cyclic ADP ribose hydrolase, Cyclin B l, CYP1B 1, Cytomegalovirus, Cytomegalovirus glycoprotein B, Dabigatran,
  • DLL4 delta-like-ligand 4
  • DPP4 Dipeptidyl-peptidase 4
  • DR5 Death receptor 5
  • E. coli shiga toxin type-1 E. coli shiga toxin type-2, ED-B, EGFL7 (EGF-like domain- containing protein 7), EGFR, EGFRII, EGFRvIII, Endoglin (CD 105), Endothelin B receptor, Endotoxin, EpCAM (epithelial cell adhesion molecule), EphA2, Episialin, ERBB2 (Epidermal Growth Factor Receptor 2), ERBB3, ERG (TMPRSS2 ETS fusion gene), Escherichia coli, ETV6-AML, FAP (Fibroblast activation protein alpha), FCGR1, alpha-Fetoprotein, Fibrin II, beta chain, Fibronectin extra domain-B, FOLR (folate receptor), Folate receptor alpha, Folate hydrolase, Fo
  • GMCSF receptor a-chain Growth differentiation factor 8
  • GP100 GPNMB
  • GUCY2C (Guanylate cyclase 2C, guanylyl cyclase C(GC-C), intestinal Guanylate cyclase, Guanylate cyclase-C receptor, Heat-stable entero- toxin receptor (hSTAR)), Heat shock proteins, Hemagglutinin, Hepatitis B surface antigen, Hepatitis B virus, HER1 (human epidermal growth factor receptor 1), HER2, HER2/neu,
  • HER3 (ERBB-3), IgG4, HGF/SF (Hepatocyte growth factor/scatter factor), HHGFR, HIV- 1, Histone complex, HLA-DR (human leukocyte antigen), HLA-DR10, HLA-DRB , HMWMAA, Human chorionic gonadotropin, HNGF, Human scatter factor receptor kinase, HPV E6/E7, Hsp90, hTERT, ICAM-1 (Intercellular Adhesion Molecule 1), Idiotype, IGF1R (IGF-1, insulin-like growth factor 1 receptor), IGHE, IFN- ⁇ , Influeza hemagglutinin, IgE, IgE Fc region, IGHE, IL-1, IL-2 receptor (interleukin 2 receptor), IL-4, IL-5, IL-6, IL-6R (interleukin 6 receptor), IL-9, IL-10, IL-12, IL-13, IL-17, IL-17A, IL-20,
  • KIR2D KIR2D, LCK, Le, Legumain, Lewis- Y antigen, LFA-1 (Lymphocyte function-associated antigen 1, CDl la), LHRH, LINGO-1, Lipoteichoic acid, LIV1A, LMP2, LTA, MAD-CT- 1, MAD-CT-2, MAGE-1, MAGE-2, MAGE-3, MAGE Al, MAGE A3, MAGE 4, MARTI, MCP-1, MIF (Macrophage migration inhibitory factor, or glycosylation- inhibiting factor (GIF)), MS4A1 (membrane- spanning 4-domains subfamily A member 1),
  • MSLN mesothelin
  • MUCl Mucin 1, cell surface associated (MUC1) or polymorphic epithelial mucin (PEM)
  • MUC1-KLH MUC16 (CA125), MCPl(monocyte chemotactic protein 1)
  • MelanA/MARTl MEG1
  • MPG MEG1
  • MS4A1 membrane-spanning 4-domains subfamily A
  • MYCN Myelin- associated glycoprotein
  • Myostatin Myostatin
  • NA17 NARP-1
  • NCA- 90 granulocyte antigen
  • Nectin-4 ASG-22ME
  • NGF Neural apoptosis-regulated proteinase 1, NOGO-A, Notch receptor, Nucleolin, Neu oncogene product, NY-BR-1, NY- ESO-1, OX-40, OxLDL (Oxidized low-density lipoprotein), OY-TES 1, P21, p53 nonmutant, P97, Page4, PAP, Paratope
  • Phosphatidylserine Prostatic carcinoma cells, Pseudomonas aeruginosa, PSMA, PSA, PSCA, Rabies virus glycoprotein, RHD (Rh polypeptide 1 (RhPI), CD240), Rhesus factor, RANKL, RhoC, Ras mutant, RGS5, ROBO4, Respiratory syncytial virus, RON, Sarcoma translocation breakpoints, SART3, Sclerostin, SLAMF7 (SLAM family member
  • TGF-C Tenascin C
  • TGF-a TGF- ⁇
  • TGF- ⁇ Transforming growth factor beta
  • TGF- ⁇ TGF ⁇ 2
  • Tie CD202b
  • Tie2 Tie2
  • TIM-1 CDX-014
  • Tn TNF, TNF-a
  • TNFRSF8 TNFRSF10B
  • TNFRSF13B tumor necrosis factor receptor superfamily member 13B
  • TPBG trophoblast glycoprotein
  • TRAIL-R1 Tuor necrosis apoprosis Inducing ligand Receptor 1
  • TRAILR2 Death receptor 5 (DR5)
  • tumor specific glycosylation of MUC1, TWEAK receptor TRP-2
  • Tyrosinase VCAM-1 (CD 106)
  • the cell-binding ligand-drug conjugates via the bridge linkers of this invention are used for the targeted treatment of cancers.
  • the targeted cancers include, but are not limited, Adrenocortical Carcinoma, Anal Cancer, Bladder Cancer, Brain Tumor (Adult, Brain Stem Glioma, Childhood, Cerebellar Astrocytoma, Cerebral
  • Gallbladder Cancer Gastric Cancer (Stomach), Germ Cell Tumor, Extragonadal, Gestational Trophoblastic Tumor, Head and Neck Cancer, Hypopharyngeal Cancer, Islet Cell Carcinoma, Kidney Cancer (renal cell cancer), Laryngeal Cancer, Leukemia (Acute Lymphoblastic, Acute Myeloid, Chronic Lymphocytic, Chronic Myelogenous, Hairy Cell), Lip and Oral Cavity Cancer, Liver Cancer, Lung Cancer (Non-Small Cell, Small Cell, Lymphoma (AIDS -Related, Central Nervous System, Cutaneous T-Cell, Hodgkin's Disease, Non-Hodgkin's Disease, Malignant Mesothelioma, Melanoma, Merkel Cell Carcinoma, Metasatic Squamous Neck Cancer with Occult Primary, Multiple Myeloma, and Other Plasma Cell Neoplasms, Mycosis Fungoides, Myelodysplastic Syndrome, Myeloproli-
  • Osteosarcoma Osteosarcoma, Ovarian Cancer (Epithelial, Germ Cell Tumor, Low Malignant Potential Tumor), Pancreatic Cancer (Exocrine, Islet Cell Carcinoma), Paranasal Sinus and Nasal Cavity Cancer, Parathyroid Cancer, Penile Cancer, Pheochromocytoma Cancer, Pituitary Cancer, Plasma Cell Neoplasm, Prostate Cancer Rhabdomyosarcoma, Rectal Cancer, Renal Cell Cancer (kidney cancer), Renal Pelvis and Ureter (Transitional Cell),
  • Salivary Gland Cancer Sezary Syndrome, Skin Cancer, Skin Cancer (Cutaneous T-Cell Lymphoma, Kaposi's Sarcoma, Melanoma), Small Intestine Cancer, Soft Tissue Sarcoma, Stomach Cancer, Testicular Cancer, Thymoma (Malignant), Thyroid Cancer, Urethral Cancer, Uterine Cancer (Sarcoma), Unusual Cancer of Childhood, Vaginal Cancer, Vulvar Cancer, Wilms' Tumor.
  • the cell-binding-drug conjugates via the bridge likers of this invention are used in accordance with the compositions and methods for the treat- ment or prevention of an autoimmune disease.
  • the autoimmune diseases include, but are not limited, Achlorhydra Autoimmune Active Chronic Hepatitis, Acute Disseminated Encephalomyelitis, Acute hemorrhagic leukoencephalitis, Addison's Disease,
  • Haemolytic anaemia Henoch- Schonlein purpura, Herpes gestationis, Hidradenitis suppurativa, Hughes syndrome (See Antiphospholipid syndrome), Hypogammaglobulinemia, Idiopathic Inflammatory Demyelinating Diseases, Idiopathic pulmonary fibrosis, Idiopathic thrombocytopenic purpura (See Autoimmune thrombocytopenic purpura), IgA nephropathy (Also Berger's disease), Inclusion body myositis, Inflammatory demyelinating polyneuopathy, Interstitial cystitis, Irritable Bowel Syndrome , Juvenile idiopathic arthritis, Juvenile rheumatoid arthritis, Kawasaki's Disease, Lambert-Eaton myasthenic syndrome, Leukocytoclastic vasculitis, Lichen planus, Lichen sclerosus, Linear IgA disease (LAD), Lou Gehrig's Disease (Als
  • Neuromyotonia Occular cicatricial pemphigoid, Opsoclonus myoclonus syndrome, Ord thyroiditis, Palindromic rheumatism, PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcus), Paraneoplastic cerebellar degeneration, Paroxysmal nocturnal hemoglobinuria, Parry Romberg syndrome, Parsonnage-Turner syndrome, Pars planitis, Pemphigus, Pemphigus vulgaris, Pernicious anaemia, Perivenous encephalo- myelitis, POEMS syndrome, Polyarteritis nodosa, Polymyalgia rheumatica, Polymyositis,
  • a binding molecule used for the conjugate via the bridge linkers of this invention for the treatment or prevention of an autoimmune disease can be, but are not limited to, anti-elastin antibody; Abys against epithelial cells antibody;
  • Anti-Basement Membrane Collagen Type IV Protein antibody Anti-Nuclear Antibody; Anti ds DNA; Anti ss DNA, Anti Cardiolipin Antibody IgM, IgG; anti-celiac antibody; Anti Phospholipid Antibody IgK, IgG; Anti SM Antibody; Anti Mitochondrial Antibody; Thyroid Antibody; Microsomal Antibody, T-cells antibody; Thyroglobulin Antibody, Anti SCL-70; Anti- Jo; Anti-U.sub.lRNP; Anti-La/SSB; Anti SSA; Anti SSB; Anti Perital Cells Antibody; Anti Histones; Anti RNP; C-ANCA; P-ANCA; Anti centromere; Anti- Fibrillarin, and Anti GBM Antibody, Anti-ganglioside antibody; Anti-Desmogein 3 antibody; Anti-p62 antibody; Anti-s lOO antibody; Anti-Mitochondrial(M2) antibody; Rheu- matoid factor antibody; Anti-MCV antibody; Anti
  • the binding molecule for the conjugate in the present invention can bind to both a receptor and a receptor complex expressed on an activated lymphocyte which is associated with an autoimmune disease.
  • the receptor or receptor complex can comprise an immunoglobulin gene superfamily member (e.g. CD2, CD3,
  • useful cell binding ligands that are immuno specific for a viral or a microbial antigen are humanized or human monoclonal antibodies.
  • viral antigen includes, but is not limited to, any viral peptide, polypeptide protein (e.g. HIV gpl20, HIV nef, RSV F glycoprotein, influenza virus neuramimi- dase, influenza virus hemagglutinin, HTLV tax, herpes simplex virus glycoprotein (e.g. gB, gC, gD, and gE) and hepatitis B surface antigen) that is capable of eliciting an immune response.
  • polypeptide protein e.g. HIV gpl20, HIV nef, RSV F glycoprotein
  • influenza virus neuramimi- dase influenza virus hemagglutinin
  • HTLV tax herpes simplex virus glycoprotein
  • herpes simplex virus glycoprotein e.g. gB, gC, gD, and gE
  • microbial antigen includes, but is not limited to, any microbial peptide, polypeptide, protein, saccharide, polysaccharide, or lipid molecule (e.g., a bacteria, fungi, pathogenic protozoa, or yeast polypeptides including, e.g., LPS and capsular polysaccharide 5/8) that is capable of eliciting an immune response.
  • microbial antigen includes, but is not limited to, any microbial peptide, polypeptide, protein, saccharide, polysaccharide, or lipid molecule (e.g., a bacteria, fungi, pathogenic protozoa, or yeast polypeptides including, e.g., LPS and capsular polysaccharide 5/8) that is capable of eliciting an immune response.
  • antibodies available 1 for the viral or microbial infection include, but are not limited to, Palivizumab which is a humanized anti-respiratory syncytial virus monoclonal antibody for the treatment of RSV infection; PRO542 which is a CD4 fusion antibody for the treatment of HIV infection; Ostavir which is a human antibody for the treatment of hepatitis B virus; PROTVIR which is a humanized IgG.sub. l antibody for the treatment of cytomegalovirus; and anti-LPS antibodies.
  • Palivizumab which is a humanized anti-respiratory syncytial virus monoclonal antibody for the treatment of RSV infection
  • PRO542 which is a CD4 fusion antibody for the treatment of HIV infection
  • Ostavir which is a human antibody for the treatment of hepatitis B virus
  • PROTVIR which is a humanized IgG.sub. l antibody for the treatment of cytomegalovirus
  • anti-LPS antibodies anti-LPS antibodies.
  • infectious diseases include, but are not limited to, Acinetobacter infections, Actinomycosis, African sleeping sickness (African trypanosomiasis), AIDS (Acquired immune deficiency syndrome), Amebiasis, Anaplasmosis, Anthrax, Arcanobacterium haemolyticum infection, Argentine hemorrhagic fever, Ascariasis, Aspergillosis, Astrovirus infection, Babesiosis, Bacillus cereus infection, Bacterial pneumonia, Bacterial vaginosis, Bacteroides infection, Balantidiasis,
  • Baylisascaris infection BK virus infection, Black piedra, Blastocystis hominis infection, Blastomycosis, Venezuelan hemorrhagic fever, Borrelia infection, Botulism (and Infant botulism), Brazilian hemorrhagic fever, Brucellosis, Burkholderia infection, Buruli ulcer,
  • Calicivirus infection (Norovirus and Sapovirus), Campylobacteriosis, Candidiasis
  • Acute coryza Creutzfeldt-Jakob disease, Crimean-Congo hemorrhagic fever, Cryptococcosis, Cryptosporidiosis, Cutaneous larva migrans, Cyclosporiasis, Cysticercosis, Cytomegalovirus infection, Dengue fever, Dientamoebiasis, Diphtheria, Diphyllobothriasis, Dracunculiasis, Ebola hemorrhagic fever, Echinococcosis, Ehrlichiosis, Enterobiasis (Pinworm infection), Enterococcus infection, Enterovirus infection, Epidemic typhus,
  • Erythema infectiosum (Fifth disease), Exanthem subitum, Fasciolopsiasis, Fasciolosis, Fatal familial insomnia, Filariasis, Food poisoning by Clostridium perfringens, Free-living amebic infection, Fusobacterium infection, Gas gangrene (Clostridial myonecrosis), Geotrichosis, Gerstmann-Straussler-Scheinker syndrome, Giardiasis, Glanders, Gnathosto- miasis, Gonorrhea, Granuloma inguinale (Donovanosis), Group A streptococcal infection,
  • Group B streptococcal infection Haemophilus influenzae infection, Hand, foot and mouth disease (HFMD), Hantavirus Pulmonary Syndrome, Helicobacter pylori infection, Hemolytic-uremic syndrome, Hemorrhagic fever with renal syndrome, Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis D, Hepatitis E, Herpes simplex, Histoplasmosis, Hookworm infec- tion, Human bocavirus infection, Human ewingii ehrlichiosis, Human granulocytic anaplasmosis, Human metapneumo virus infection, Human monocytic ehrlichiosis, Human papillomavirus infection, Human parainfluenza virus infection, Hymenolepiasis, Epstein- Barr Virus Infectious Mononucleosis (Mono), Influenza, Isosporiasis, Kawasaki disease, Keratitis, Kingella kingae infection, Kuru
  • Molluscum contagiosum Mumps, Murine typhus (Endemic typhus), Mycoplasma pneumonia, Mycetoma, Myiasis, Neonatal conjunctivitis (Ophthalmia neonatorum), (New) Variant Creutzfeldt-Jakob disease (vCJD, nvCJD), Nocardiosis, Onchocerciasis (River blindness), Paracoccidioidomycosis (South American blastomycosis), Paragonimiasis, Pasteurellosis, Pediculosis capitis (Head lice), Pediculosis corporis (Body lice), Pediculosis pubis (Pubic lice, Crab lice), Pelvic inflammatory disease, Pertussis (Whooping cough),
  • Tinea manuum (Ringworm of the Hand), Tinea nigra, Tinea pedis (Athlete's foot), Tinea unguium (Onychomycosis), Tinea versicolor (Pityriasis versicolor), Toxocariasis (Ocular Larva Migrans), Toxocariasis (Visceral Larva Migrans), Toxoplasmosis, Trichinellosis, Trichomoniasis, Trichuriasis (Whipworm infection), Tuberculosis, Tularemia, Ureaplasma urealyticum infection, Venezuelan equine encephalitis, Venezuelan hemorrhagic fever,
  • Viral pneumonia West Nile Fever, White piedra (Tinea blanca), Yersinia pseudotuberculosis infection, Yersiniosis, Yellow fever, Zygomycosis.
  • the cell binding molecule which is more preferred to be an antibody described in this patent that are against pathogenic strains include, but are not limit, Acinetobacter baumannii, Actinomyces israelii, Actinomyces gerencseriae and Propionibacterium propionicus, Trypanosoma brucei, HIV (Human immunodeficiency virus), Entamoeba histolytica, Anaplasma genus, Bacillus anthracis, Arcanobacterium haemolyticum, Junin virus, Ascaris lumbricoides, Aspergillus genus, Astroviridae family, Babesia genus, Bacillus cereus, multiple bacteria, Bacteroides genus, Balantidium coli, Baylisascaris genus, BK virus, Piedraia hortae, Blastocystis hominis, Blastomyces dermatitides, Machupo virus, Borrelia genus, Clostridium bot
  • Cyclospora cayetanensis Taenia solium, Cytomegalovirus, Dengue viruses (DEN-1, DEN- 2, DEN-3 and DEN-4) - Flaviviruses, Dientamoeba fragilis, Corynebacterium diphtheriae, Diphyllobothrium, Dracunculus medinensis, Ebolavirus, Echinococcus genus, Ehrlichia genus, Enterobius vermicularis, Enterococcus genus, Enterovirus genus, Rickettsia prowazekii, Parvovirus B 19, Human herpesvirus 6 and Human herpesvirus 7, Fasciolopsis buski, Fasciola hepatica and Fasciola gigantica, FFI prion, Filarioidea superfamily, Clostridium perfringens, Fusobacterium genus, Clostridium perfringens; other Clostridium species, Geotrichum candidum, GSS pri
  • Enteroviruses mainly Coxsackie A virus and Enterovirus 71, Sin Nombre virus, Helicobacter pylori, Escherichia coli O157:H7, Bunyaviridae family, Hepatitis A Virus, Hepatitis B Virus, Hepatitis C Virus, Hepatitis D Virus, Hepatitis E Virus, Herpes simplex virus 1, Herpes simplex virus 2, Histoplasma capsulatum, Ancylostoma duodenale and Necator americanus, Hemophilus influenzae, Human bocavirus, Ehrlichia ewingii, Anaplasma phagocytophilum, Human metapneumovirus, Ehrlichia chaffeensis, Human papillomavirus, Human parainfluenza viruses, Hymenolepis nana and Hymenolepis diminuta, Ep- stein-Barr Virus, Orthomy-xoviridae family, Isospora belli
  • Trichophyton genus Trichophyton tonsurans, Trichophyton genus, Epidermophyton floccosum, Trichophyton rubrum, and Trichophyton mentagrophytes, Trichophyton rubrum, Hortaea wasneckii, Trichophyton genus, Malassezia genus, Toxocara canis or Toxocara cati, Toxoplasma gondii, Trichinella spiralis, Trichomonas vaginalis, Trichuris trichiura, Mycobacterium tuberculosis, Francisella tularensis, Ureaplasma urealyticum,
  • Venezuelan equine encephalitis virus Vibrio colerae, Guanarito virus, West Nile virus, Trichosporon beigelii, Yersinia pseudotuberculosis, Yersinia enterocolitica, Yellow fever virus, Mucorales order (Mucormycosis) and Entomophthorales order (Entomophthora- mycosis), Pseudomonas aeruginosa, Campylobacter (Vibrio) fetus, Aeromonas hydrophila, Edwardsiella tarda, Yersinia pestis, Shigella dysenteriae, Shigella flexneri, Shigella sonnei,
  • Salmonella typhimurium, Treponema per pneumonia, Treponema carateneum, Borrelia vincentii, Borrelia burgdorferi, Leptospira icterohemorrhagiae, Pneumocystis carinii, Brucella abortus, Brucella suis, Brucella melitensis, Mycoplasma spp., Rickettsia prowazeki, Rickettsia tsutsugumushi, Clamydia spp.; pathogenic fungi (Aspergillus fumigatus, Candida albicans, Histoplasma capsulatum); protozoa (Entomoeba histolytica, Trichomonas tenas,
  • Trichomonas hominis Tryoanosoma gambiense, Trypanosoma rhodesiense, Leishmania donovani, Leishmania tropica, Leishmania braziliensis, Pneumocystis pneumonia, Plasmodium vivax, Plasmodium falciparum, Plasmodium malaria); or Helminiths (Schistosoma japonicum, Schistosoma mansoni, Schistosoma haematobium, and hookworms).
  • antibodies as cell binding ligands used in this invention for treatment of viral disease include, but are not limited to, antibodies against antigens of pathogenic viruses, including as examples and not by limitation: Poxyiridae, Herpesviridae, Adenoviridae, Papovaviridae, Enteroviridae, Picornaviridae, Parvoviridae, Reoviridae, Retroviridae, influenza viruses, parainfluenza viruses, mumps, measles, respiratory syncytial virus, rubella, Arboviridae, Rhabdoviridae, Arenaviridae, Non-A/Non-B Hepatitis virus, Rhinoviridae, Coronaviridae, Rotoviridae, Oncovirus [such as, HBV (Hepatocellular carcinoma), HPV (Cervical cancer, Anal cancer), Kaposi's sarcoma-associated herpesvirus (Kaposi's sarcoma), Epstein-Barr virus (Nas
  • the present invention also concerns pharmaceutical compositions comprising the conjugate via the bridge linkers of the invention together with a pharmaceutically acceptable carrier, diluent, or excipient for treatment of cancers, infections or autoimmune disorders.
  • a pharmaceutically acceptable carrier diluent, or excipient for treatment of cancers, infections or autoimmune disorders.
  • the method for treatment of cancers, infections and autoimmune disorders can be practiced in vitro, in vivo, or ex vivo.
  • in vitro uses include treatments of cell cultures in order to kill all cells except for desired variants that do not express the target antigen; or to kill variants that express undesired antigen.
  • ex vivo uses include treatments of hematopoietic stem cells (HSC) prior to the performance of the transplantation (HSCT) into the same patient in order to kill diseased or malignant cells.
  • HSC hematopoietic stem cells
  • the bone marrow cells are washed with medium containing serum and returned to the patient by i.v. infusion according to known methods.
  • the treated marrow cells are stored frozen in liquid nitrogen using standard medical equipment.
  • the conjugate via the linkers of the invention will be supplied as solutions or as a lyophilized solid that can be redissolved in sterile water for injection.
  • suitable protocols of conjugate administration are as follows. Conjugates are given weekly for 8-20 weeks as an i.v. bolus. Bolus doses are given in 50 to 500 ml of normal saline to which human serum albumin (e.g. 0.5 to 1 mL of a concentrated solution of human serum albumin, 100 mg/mL) can be added. Dosages will be about 50 ⁇ g to 20 mg/kg of body weight per week, i.v. (range of 10 ⁇ g to 200 mg/kg per injection). 4-20 weeks after treatment, the patient may receive a second course of treatment. Specific clinical protocols with regard to route of administration, excipients, diluents, dosages, times, etc., can be determined by the skilled clinicians.
  • Examples of medical conditions that can be treated according to the in vivo or ex vivo methods of killing selected cell populations include malignancy of any types of cancer, autoimmune diseases, graft rejections, and infections (viral, bacterial or parasite).
  • the amount of a conjugate which is required to achieve the desired biological effect will vary depending upon a number of factors, including the chemical characteristics, the potency, and the bioavailability of the conjugates, the type of disease, the species to which the patient belongs, the diseased state of the patient, the route of administration, all factors which dictate the required dose amounts, delivery and regimen to be administered.
  • the conjugates via the linkers of this invention may be provided in an aqueous physiological buffer solution containing 0.1 to 10% w/v conjugates for parenteral administration.
  • Typical dose ranges are from 1 g/kg to 0.1 g/kg of body weight per day; a preferred dose range is from 0.01 mg/kg to 20 mg/kg of body weight per day, or per week, or an equivalent dose in a human child.
  • the preferred dosage of drug to be administered is likely to depend on such variables as the type and extent of progression of the disease or disorder, the overall health status of the particular patient, the relative biological efficacy of the compound selected, the formulation of the compound, the route of administration
  • the conjugates via the linkers of the present invention are also capable of being ad- ministered in unit dose forms, wherein the term "unit dose” means a single dose which is capable of being administered to a patient, and which can be readily handled and packaged, remaining as a physically and chemically stable unit dose comprising either the active conjugate itself, or as a pharmaceutically acceptable composition, as described hereinafter.
  • unit doses for humans range from 1 mg to 3000 mg per day, or per week, per two week or per month.
  • the unit dose range is from 1 to 500 mg administered one to four times a week, and even more preferably from 1 mg to 100 mg, once a week.
  • Conjugates provided herein can be formulated into pharmaceutical compositions by admixture with one or more pharmaceutically acceptable excipients.
  • Such unit dose compositions may be prepared for use by oral administration, particularly in the form of tablets, simple capsules or soft gel capsules; or intranasal, particularly in the form of powders, nasal drops, or aerosols; or dermally, for example, topically in ointments, creams, lotions, gels or sprays, or via trans-dermal patches.
  • Drugs that can be conjugated to a cell-binding molecule in the present invention are small molecule drugs including cytotoxic agents, which can be linked to or after they are modified for linkage to the cell-binding agent.
  • a "small molecule drug” is broadly used herein to refer to an organic, inorganic, or organometallic compound that may have a molecular weight of for example 100 to 1800, more suitably from 120 to 1400.
  • Small molecule drugs are well characterized in the art, such as in WO05058367A2, and in U.S. Patent No. 4,956,303, among others and are incorporated in their entirety by reference.
  • the drugs include known drugs and those that may become known drugs.
  • Drugs that are known include, but not limited to,
  • Chemotherapeutic agents a).
  • Alkylating agents such as Nitrogen mustards:
  • Plant Alkaloids such as Vinca alkaloids: (vincristine, vinblastine, vindesine, vinorelbine, navelbin); Taxoids: (paclitaxel, docetaxol) and their analogs, Maytansinoids (DM1, DM2, DM3, DM4, maytansine and ansamitocins) and their analogs, cryptophycins (particularly cryptophycin 1 and cryptophycin 8); epothilones, eleutherobin, discodermo- lide, bryostatins, dolostatins, auristatins, tubulysins, cephalostatins; pancratistatin; a sarcodictyin; spongistatin; c).
  • DNA Topoisomerase Inhibitors such as [Epipodophyllins:
  • Anti-metabolites such as ⁇ [Anti-folate: DHFR inhibitors: (methotrexate, trimetrexate, denopterin, pteropterin, aminopterin (4-aminopteroic acid) or the other folic acid analogues); IMP dehydrogenase
  • Inhibitors (mycophenolic acid, tiazofurin, ribavirin, EICAR); Ribonucleotide reductase Inhibitors: (hydroxyurea, deferoxamine)]; [Pyrimidine analogs: Uracil analogs:
  • Cytosine analogs (cytarabine, cytosine arabinoside, fludarabine); Purine analogs: (azathioprine, fludarabine, mercaptopurine, thiamiprine, thioguanine)]; folic acid replenisher, such as frolinic acid ⁇ ; e).
  • Hormonal therapies such as ⁇ Receptor antagonists: [Anti-estrogen: (megestrol, raloxifene, tamoxifen); LHRH agonists: (goscrclin, leuprolide acetate); Anti-androgens: (bicalutamide, flutamide, calusterone, dromostanolone propionate, epitiostanol, goserelin, leuprolide, mepitiostane, nilutamide, testolactone, trilostane and other androgens inhibitors)]; Retinoids/Deltoids: [Vitamin D3 analogs: (CB 1093, EB 1089 KH 1060, cholecalciferol, ergocalciferol); Photodynamic therapies: (verteporfin, phthalocyanine, photo sensitizer Pc4, demethoxy-hypocrellin A); Cytokines: (Interferon- alpha, Interfer
  • Kinase inhibitors such as BIBW 2992 (anti-EGFR/Erb2), imatinib, gefitinib, pegaptanib, sorafenib, dasatinib, sunitinib, erlotinib, nilotinib, lapatinib, axitinib, pazopanib.
  • vandetanib E7080 (anti-VEGFR2), mubritinib, ponatinib (AP24534), bafetinib (INNO-406), bosutinib (SKI-606), cabozantinib, vismodegib, iniparib, ruxolitinib, CYT387, axitinib, tivozanib, sorafenib, bevacizumab, cetuximab, Trastuzumab,
  • antibiotics such as the enediyne antibiotics (e.g. calicheamicins, especially calicheamicin ⁇ , ⁇ , ⁇ 1 and ⁇ 1, see, e.g., J. Med. Chem., 39 (11), 2103-2117 (1996), Angew Chem Intl. Ed. Engl.
  • enediyne antibiotics e.g. calicheamicins, especially calicheamicin ⁇ , ⁇ , ⁇ 1 and ⁇ 1, see, e.g., J. Med. Chem., 39 (11), 2103-2117 (1996), Angew Chem Intl. Ed. Engl.
  • dynemicin including dynemicin A and deoxydynemicin; esperamicin, kedarcidin, C-1027, maduropeptin, as well as neocarzinostatin chromophore and related chromoprotein enediyne antiobiotic chromomophores), aclacinomysins, actinomycin, authramycin, azaserine, bleomycins, cactinomycin, carabicin, carminomycin, carzinophilin;
  • chromomycins dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, doxorubicin, morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino- doxorubicin and deoxydoxorubicin, epirubicin, esorubicin, idarubicin, marcellomycin, nitomycins, mycophenolic acid, nogalamycin, olivomycins, peplomycin, potfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin; f).
  • Celecoxib glitazones, epigallocatechin gallate, Disulfiram, Salinosporamide A.; Anti- adrenals, such as aminoglutethimide, mitotane, trilostane; aceglatone; aldophosphamide glycoside; aminolevulinic acid; amsacrine; arabinoside, bestrabucil; bisantrene; edatraxate; defofamine; demecolcine; diaziquone; eflornithine (DFMO), elfomithine; elliptinium acetate, etoglucid; gallium nitrate; gacytosine, hydroxyurea; ibandronate, lentinan;
  • Anti- adrenals such as aminoglutethimide, mitotane, trilostane; aceglatone; aldophosphamide glycoside; aminolevulinic acid; amsacrine; arabinoside, bestrabucil;
  • lonidamine mitoguazone; mitoxantrone; mopidamol; nitracrine; pentostatin; phenamet; pirarubicin; podophyllinic acid; 2-ethylhydrazide; procarbazine; PSK ® ; razoxane; rhizoxin; sizofiran; spirogermanium; tenuazonic acid; triaziquone; 2, 2',2"-trichlorotriethylamine; trichothecenes (especially T-2 toxin, verrucarin A, roridin A and anguidine); urethane, siRNA, antisense drugs, and a nucleolytic enzyme.
  • An anti- autoimmune disease agent includes, but is not limited to, cyclosporine, cyclosporin A, aminocaproic acid, azathioprine, bromocriptine, chlorambucil, chloroquine, cyclophosphamide, corticosteroids (e.g. amcinonide, betamethasone, budesonide, hydrocortisone, flunisolide, fluticasone propionate, f uocortolone danazol, dexamethasone, Triamcinolone acetonide, beclometasone dipropionate), DHEA, enanercept,
  • corticosteroids e.g. amcinonide, betamethasone, budesonide, hydrocortisone, flunisolide, fluticasone propionate, f uocortolone danazol, dexamethasone, Triamcinolone acetonide, beclometasone diprop
  • An anti-infectious disease agent includes, but is not limited to, a).
  • Aminoglycosides amikacin, astromicin, gentamicin (netilmicin, sisomicin, isepamicin), hygromycin B, kanamycin (amikacin, arbekacin, bekanamycin, dibekacin, tobramycin), neomycin
  • carbacephem (loracarbef), cefacetrile, cefaclor, cefradine, cefadroxil, cefalonium, cefaloridine, cefalotin or cefalothin, cefalexin, cefaloglycin, cefamandole, cefapirin, cefatrizine, cefazaflur, cefazedone, cefazolin, cefbuperazone, cefcapene, cefdaloxime, cefepime, cefminox, cefoxitin, cefprozil, cefroxadine, ceftezole, cefuroxime, cefixime, cefdinir, cefditoren, cefepime, cefetamet, cefmenoxime, cefodizime, cefonicid, cefoperazone, ceforanide, cefotaxime, cefotiam, cefozopran, cephalexin, cefp
  • Glycopeptides bleomycin, vancomycin (oritavancin, telavancin), teicoplanin (dalbavancin), ramoplanin; g).
  • Glycylcyc lines e. g. tigecycline; g).
  • ⁇ - Lactamase inhibitors penam (sulbactam, tazobactam), clavam (clavulanic acid); i).
  • Lincosamides clindamycin, lincomycin; j). Lipopeptides: daptomycin, A54145, calcium-dependent antibiotics (CDA); k). Macrolides: azithromycin, cethromycin, clarithromycin, dirithromycin, erythromycin, flurithromycin, josamycin, ketolide (telithromycin, cethromycin), midecamycin, miocamycin, oleandomycin, rifamycins (rifampicin, rifampin, rifabutin, rifapentine), rokitamycin, roxithromycin, spectinomycin, spiramycin, tacrolimus (FK506), troleandomycin, telithromycin; 1).
  • Monobactams aztreonam, tigemonam; m).
  • Oxazolidinones linezolid; n).
  • Penicillins amoxicillin, ampicillin (pivampicillin, hetacillin, bacampicillin, metampicillin, talampicillin), azidocillin, azlocillin, benzylpenicillin, benzathine benzylpenicillin, benzathine phenoxymethyl-penicillin, clometocillin, procaine benzylpenicillin, carbenicillin (carindacillin), cloxacillin, dicloxacillin, epicillin, flucloxacillin, mecillinam (pivmecillinam), mezlocillin, meticillin, nafcillin, oxacillin, penamecillin, penicillin, pheneticillin, phenoxymethylpenicillin, piperacillin, propicillin, sulbeniciUin, temocillin
  • Streptogramins pristinamycin, quinupristin/dalfopristin); r).
  • Sulfonamides mafenide, prontosil, sulfacetamide, sulfamethizole, sulfanilimide, sulfasalazine, sulfisoxazole, trimethoprim, trimethoprim- sulfamethoxazole (co-trimoxazole); s).
  • Steroid antibacterials e.g. fusidic acid; t).
  • Tetracyclines doxycycline, chlortetracycline, clomocycline,
  • demeclocycline demeclocycline, lymecycline, meclocycline, metacycline, minocycline, oxytetracycline, penimepicycline, rolitetracycline, tetracycline, glycylcyclines (e.g. tigecycline); u).
  • Other types of antibiotics annonacin, arsphenamine, bactoprenol inhibitors (Bacitracin),
  • DADAL/AR inhibitors cycloserine
  • dictyostatin discodermolide
  • eleutherobin epothilone
  • ethambutol etoposide
  • faropenem fusidic acid
  • furazolidone isoniazid
  • laulimalide metronidazole
  • mupirocin mycolactone
  • NAM synthesis inhibitors e. g.
  • quinupristin/dalfopristin quinupristin/dalfopristin, rifampicin (rifampin), tazobactam tinidazole, uvaricin;
  • Anti-viral drugs a). Entry/fusion inhibitors: aplaviroc, maraviroc, vicriviroc, gp41 (enfuvirtide), PRO 140, CD4 (ibalizumab); b). Integrase inhibitors: raltegravir,
  • elvitegravir globoidnan A
  • Maturation inhibitors bevirimat, becon
  • Neuraminidase inhibitors oseltamivir, zanamivir, peramivir
  • Nucleosides &_nucleotides abacavir, aciclovir, adefovir, amdoxovir, apricitabine, brivudine, cidofovir, clevudine,
  • dexelvucitabine didanosine (ddl), elvucitabine, emtricitabine (FTC), entecavir, famciclovir, fluorouracil (5-FU), 3 '-fluoro-substituted 2', 3 '-dideoxynucleoside analogues
  • fLT 3'-fluoro-2',3'-dideoxythymidine
  • FLG 3'-fluoro-2',3'-dideoxyguanosine
  • fomivirsen e.g. 3'-fluoro-2',3'-dideoxythymidine (FLT) and 3'-fluoro-2',3'-dideoxyguanosine (FLG)
  • fomivirsen e.g. 3'-fluoro-2',3'-dideoxythymidine (FLT) and 3'-fluoro-2',3'-dideoxyguanosine (FLG)
  • fomivirsen e.g. 3'-fluoro-2',3'-dideoxythymidine (FLT) and 3'-fluoro-2',3'-dideoxyguanosine (FLG)
  • fomivirsen e.g. 3'-fluoro-2',3'-dideoxyth
  • Non-nucleosides amantadine, ateviridine, capravirine, diarylpyrimidines (etravirine, rilpivirine), delavirdine, docosanol, emivirine, efavirenz, foscarnet (phosphonoformic acid), imiquimod, interferon alfa, loviride, lodenosine, methisazone, nevirapine, NOV-205, peginterferon alfa,
  • Protease inhibitors amprenavir, atazanavir, boceprevir, darunavir, fosamprenavir, indinavir, lopinavir, nelfinavir, pleconaril, ritonavir, saquinavir, telaprevir (VX-950), tipranavir; h).
  • anti- virus drugs abzyme, arbidol, calanolide a, ceragenin, cyanovirin-n, diarylpyrimidines, epigallocatechin gallate (EGCG), foscarnet, griffithsin, taribavirin (viramidine), hydroxyurea, KP-1461, miltefosine, pleconaril, portmanteau inhibitors, ribavirin, seliciclib.
  • the drugs used for conjugates via a bridge linker of the present invention also in- elude radioisotopes.
  • radioisotopes radioisotopes
  • Rad ⁇ i ⁇ oi ⁇ sotope labeled antibodies are useful in receptor targeted imaging experiments or can be for targeted treatment such as with the antibody-drug conjugates of the invention (Wu et al
  • the cell binding molecules e.g. an antibody can be labeled with ligand reagents through the bridge linkers of the present patent that bind, chelate or otherwise complex a radioisotope metal, using the techniques described in Current Protocols in Immunology, Volumes 1 and 2, Coligen et al, Ed. Wiley- Interscience, New York, Pubs. (1991).
  • Chelating ligands which may complex a metal ion include DOTA, DOTP, DOTMA, DTP A and TETA (Macrocyclics, Dallas, Tex. USA).
  • the drug in the Formula (II) and (IV) can a chromophore molecule, for which the conjugate can be used for detection, monitoring, or study the interaction of the cell binding molecule with a target cell.
  • Chromophore molecules are a compound that have the ability to absorb a kind of light, such as UV light, florescent light, IR light, near IR light, visual light;
  • a chromatophore molecule includes a class or subclass of xanthophores, erythrophores, iridophores, leucophores, melanophores, and cyanophores; a class or subclass of fluorophore molecules which are fluorescent chemical compounds re- emitting light upon light; a class or subclass of visual phototransduction molecules; a class or subclass of photophore molecules; a class or subclass of luminescence molecules; and a class or subclass of luciferin compounds.
  • the chromophore molecule can be selected from, but not limited, Non-protein organic fluorophores, such as: Xanthene derivatives (fluorescein, rhodamine, Oregon green, eosin, and Texas red); Cyanine derivatives: (cyanine, indocarbocyanine, oxacarbocyanine, thiacarbocyanine, and merocyanine); Squaraine derivatives and ring-substituted squaraines, including Seta, SeTau, and Square dyes; Naphthalene derivatives (dansyl and prodan derivatives); Coumarin derivatives; Oxadiazole derivatives (pyridyloxazole, nitrobenzoxadiazole and benzoxadiazole); Anthracene derivatives (anthraquinones, including DRAQ5, DRAQ7 and CyTRAK Orange); Pyrene derivatives (cascade blue, etc); Oxazine derivatives (Nile red, Nile blue, cres
  • Acridine derivatives proflavin, acridine orange, acridine yellow etc.
  • Arylmethine derivatives auramine, crystal violet, malachite green).
  • Tetrapyrrole derivatives porphin, phthalocyanine, bilirubin.
  • a chromophore molecule can be selected from any analogs and derivatives of the following fluorophore compounds: CF dye (Biotium), DRAQ and CyTRAK probes (BioStatus), BODIPY (Invitrogen), Alexa Fluor (Invitrogen), DyLight Fluor (Thermo Scientific, Pierce), Atto and Tracy (Sigma Aldrich), FluoProbes (Interchim), Abberior
  • Dyes (Abberior), DY and MegaStokes Dyes (Dyomics), Sulfo Cy dyes (Cyandye), HiLyte Fluor (AnaSpec), Seta, SeTau and Square Dyes (SETA BioMedicals), Quasar and Cal Fluor dyes (Biosearch Technologies), SureLight Dyes (APC, RPEPerCP,
  • the fluorophore compounds that can be linked to the linkers of the invention for study of nucleic acids or proteins are selected from the following compounds or their derivatives: 7-AAD (7-aminoactinomycin D, CG-selective), Acridine Orange, Chromomycin A3, CyTRAK Orange (Biostatus, red excitation dark), DAPI, DRAQ5, DRAQ7, Ethidium Bromide, Hoechst33258, Hoechst33342, LDS 751, Mithramycin, Propidiumlodide (PI), SYTOX Blue, SYTOX Green, SYTOX Orange, Thiazole Orange, TO-PRO: Cyanine
  • the fluorophore compounds that can be linked to the linkers of the invention for study cells are selected from the following compounds or their derivatives: DCFH (2'7'Dichorodihydro- fluorescein, oxidized form), DHR (Dihydrorhodamine 123, oxidized form, light catalyzes oxidation), Fluo-3 (AM ester. pH > 6), Fluo-4 (AM ester. pH 7.2), Indo-1 (AM ester, low/high calcium (Ca2+)), SNARF(pH 6/9).
  • the preferred fluorophore compounds that can be linked to the linkers of the invention for study proteins/antibodies are selected from the following compounds or their derivatives: Allophycocyanin(APC), AmCyanl (tetram- er, Clontech), AsRed2 (tetramer, Clontech), Azami Green (monomer, MBL), Azurite, B- phycoerythrin(BPE), Cerulean, CyPet, DsRed monomer (Clontech), DsRed2 ("RFP",
  • the drug in the Formula (II) and (IV) can be a polyalkylene glycols that are used for extending the half-life of the cell-binding molecule when administered to a mammal.
  • Polyalkylene glycols include, but are not limited to, poly(ethylene glycols) (PEGs), poly(propylene glycol) and copolymers of ethylene oxide and propylene oxide; particularly preferred are PEGs, and more particularly preferred are
  • hydroxyPEGs e.g., hydroxyPEGs activated at a single terminus, including reactive esters of hydroxyPEG-monocarboxylic acids, hydroxyPEG- monoaldehydes, hydroxyPEG-monoamines, hydroxyPEG-monohydrazides, hydroxyPEG- monocarbazates, hydroxyPEG-monoiodoacetamides, hydroxyPEG-monomaleimides, hydroxyPEG-monoorthopyridyl disulfides, hydroxyPEG-monooximes, hydroxyPEG- monophenyl carbonates, hydroxyPEG-monophenyl glyoxals, hydroxyPEG- monothiazolidine-2-thiones, hydroxyPEG-monothioesters, hydroxyPEG-monothiols, hydroxyPEG-monotriazines and hydroxyPEG-monovinylsulfones).
  • the polyalkylene glycol has a molecular weight of from about 10 Daltons to about 200 kDa, preferably about 88 Da to about 40 kDa; two branches each with a molecular weight of about 88 Da to about 40 kDa; and more preferably two branches, each of about 88 Da to about 20 kDa.
  • the polyalkylene glycol is poly(ethylene) glycol and has a molecular weight of about 10 kDa; about 20 kDa, or about 40 kDa.
  • the PEG is a PEG 10 kDa (linear or branched), a PEG 20 kDa (linear or branched), or a PEG 40 kDa (linear or branched).
  • a number of US patents have disclosed the preparation of linear or branched "non- antigenic" PEG polymers and derivatives or conjugates thereof, e.g., U.S. Pat. Nos. 5,428,128;
  • mAb is an antibody; n is 1-30; R' and R" are independently H or CH 3 ; m 3 and m4 are independently 0-5000; " X 1, X 2 , R 1 , R 2 , and R 3 are the same defined
  • R 4 is OH, H, or R 1, or R 3 that is defined as in Formula (I).
  • the preferred cytotoxic agents that conjugated to a cell- binding molecule via a bridge linker of this patent are tubulysins, maytansinoids, taxanoids (taxanes), CC-1065 analogs, daunorubicin and doxorubicin compounds, benzodiazepine dimers (e.g., dimers of pyrrolobenzodiazepine (PBD), tomaymycin, anthramycin, indolinobenzodiazepines, imidazobenzothiadiazepines, or oxazolidino-benzodiazepines), calicheamicins and the enediyne antibiotics, actinomycin, azaserines, bleomycins, epirubicin, tamoxifen, idarubicin, dolastatins, auristatins (e.g.
  • auristatin E monomethyl auristatin E, MMAE , MMAF, auristatin PYE, auristatin TP, Auristatins 2-AQ, 6-AQ, EB (AEB), and EFP (AEFP)), duocarmycins, thiotepa, vincristines, hemiasterlins, convoumamides, microginins, radiosumins,reterobactins, microsclerodermins, theonellamides,
  • Tubulysins that are preferred for conjugation in the present invention are well known in the art and can be isolated from natural sources according to known methods or prepared synthetically according to known methods (e. g. Balasubramanian, R.; et al. J. Med.
  • T01, T02, T03, T04, T05, T06 and T07 are T01, T02, T03, T04, T05, T06 and T07 as following:
  • mAb is an antibody
  • Z 3 and Z' 3 are independently H, OP(O)(OMi)(OM 2 ), OCH 2 OP(O)(OMi)(OM 2 ), OSO 3 M 1 , R 1 , or O-glycoside (glucoside, galactoside, mannoside, glucuronoside, alloside, fructoside, etc), NH-glycoside, S-glycoside or CH 2 - glycoside;
  • M 1 and M 2 are independently H, Na, K, Ca, Mg, NH 4 , NR 1 R 2 R 3 ; n is 1-30;
  • X 1 , X 2 , R 1 , R 2 and R 3 are the same defined in Formula (I) and (II).
  • mAb is an antibody; n is 1-30; X 1 , X 2 , R 1 , R 2 and R 3 are the same defined in Formula (I) and (II).
  • Maytansinoids that are preferred to be used in the present invention including maytansinol and its analogues are described in U.S. Patent Nos. 4,256,746, 4,361,650, 4,307,016, 4,294,757, 4,294,757, 4,371,533, 4,424,219, 4,331,598, 4,450,254, 4,364,866, 4,313,946, 4,315,929 4,362,663, 4,322,348, 4,371,533, 4,424,219, 5,208,020, 5,416,064, 5,208,020; 5,416,064; 6,333.410; 6,441,163; 6,716,821, 7,276,497, 7,301,019, 7,303,749, 7,368,565, 7,411,063, 7,851,432, and 8,163,888 .
  • An example of the structure of the conjugate of the antibody- Maytansinoids via the bridge linker is as the following M01:
  • mAb is an antibody
  • n is 1 ⁇ 30
  • X 1 , X 2 , R 1 , R 2 and R 3 are the same
  • Taxanes which includes Paclitaxel (Taxol), a cytotoxic natural product, and docetaxel (Taxotere), a semi-synthetic derivative, and their analogs which are preferred for conjugation via the bridge linkers of the present patent are exampled in:. K C. Nicolaou et al., J. Am. Chem. Soc. 117, 2409-2420, (1995); Ojima et al, J. Med. Chem. 39:3889-3896 (1996); 40:267-278 (1997); 45, 5620-5623 (2002); Ojima et al., Proc. Natl. Acad.
  • Examples of the structures of the conjugate of the antibody- taxanes via the bridge linker are as the following Tx01, Tx02 and Tx03.
  • mAb is an antibody; n is 1 ⁇ 30; X 1 , X 2 , R 1 and R 2 are the same defined in Formula (I) and (II).
  • CC-1065 analogues and doucarmycin analogs are also preferred to be used for a conjugate with the bridge linkers of the present patent.
  • the examples of the CC-1065 analogues and doucarmycin analogs as well as their synthesis are described in: e.g.
  • Daunorubicin/Doxorubicin Analogues are also preferred for conjugation via the bridge linkers of the present patent.
  • the preferred structures and their synthesis are exam- pled in: Hurwitz, E., et al., Cancer Res. 35, 1175-1181 (1975). Yang, H. M., and Reisfeld, R. A., Proc. Natl. Acad. Sci. 85, 1189-1193 (1988); Pietersz, C. A., E., et al., E., et al.," Cancer Res. 48, 926-9311 (1988); Trouet, et al., 79, 626-629 (1982); Z. Brich et al., J.
  • mAb is an antibody
  • n is 1 ⁇ 30
  • X 3 and X' 3 are independently H, O, NH, NHC(O),
  • Auristatins and dolastatins are preferred in conjugation via the bridge linkers of this patent.
  • the auristatins e. g. auristain E (AE) auristatin EB (AEB), auristatin EFP (AEFP), monomethyl auristatin E (MMAE), Monomethylauristatin (MMAF), Auristatin F phenylene diamine (AFP) and a phenylalanine variant of MMAE
  • AE auristain E
  • AEB auristatin EFP
  • MMAE monomethyl auristatin E
  • MMAF Monomethylauristatin
  • AFP Auristatin F phenylene diamine
  • AFP phenylalanine variant of MMAE
  • benzodiazepine dimers e. g. dimmers of pyrrolobenzodiazepine (PBD) or (tomaymycin), indolinobenzodiazepines, imidazobenzothiadiazepines, or
  • oxazolidinobenzodiazepines which are preferred cytotoxic agents according to the present invention are exampled in the art: US Patent Nos . 8,163,736; 8,153,627; 8,034,808;
  • X 1 , X 2 , R 1, R 2 and R 3 are the same defined in Formula (I) and (II).
  • R 1 and/or R 2 can be absent.
  • two or more different cytotoxic agents are preferred conjugated to a cell-binding molecule via a bridge linker of this patent.
  • the two or more different cytotoxic agents can be selected from any combinations of tubulysins, maytansinoids, taxanoids (taxanes), CC-1065 analogs, daunorubicin and doxorubicin compounds, benzodiazepine dimers (e.g., dimers of pyrrolobenzodiazepine (PBD), tomaymycin, anthramycin, indolinobenzodiazepines, imidazobenzothiadiazepines, or oxazolidino-benzodiazepines), calicheamicins and the enediyne antibiotics, actinomycin, azaserines, bleomycins, epirubicin, tamoxifen, idarubicin, dolastatins, auristatins (e.g.
  • auristatin E monomethyl auristatin E, MMAE , MMAF, auristatin PYE, auristatin TP, Auristatins 2- AQ, 6-AQ, EB (AEB), and EFP (AEFP)), duocarmycins, thiotepa, vincristines, hemiasterlins, soloumamides, microginins, radiosumins,reterobactins, microsclerodermins, theonellamides, esperamicins, PNU- 159682, and their analogues and derivatives above thereof.
  • Examples of the structures of the conjugates containing two or more different cytotoxic agents via the bridge linker are as the following Z01, Z02, Z02, Z04, Z05, Z06,
  • R 1 and/or R 2 are the same defined in Formula (I) and (II).
  • R 1 and/or R 2 can be absent.
  • cell-binding ligands or receptors can be conjugated to a cell-binding molecule via a bridge linker of this patent.
  • These conjugated cell-binding ligands or receptors in particular, antibody-receptor conjugates, can be not only to work as a targeting conductor/director to deliver the conjugate to malignant cells, but also be used to modulate or co-stimulate a desired immune response or altering signaling pathways.
  • the cell-binding ligands or receptors are preferred to conjugate to an antibody of TCR (T cell receptors) T cell, or of CARs (chimeric antigen receptors) T cells, or of B cell receptor (BCR), or the cytotoxic cells.
  • the cell-binding ligands or receptors are selected, but not limited, from: Folate derivatives (binding to the folate receptor, a protein over-expressed in ovarian cancer and in other malignancies) (Low, P. S. et al 2008, Acc. Chem. Res. 41, 120-129); Glutamic acid urea derivatives (binding to the prostate specific membrane antigen, a surface marker of prostate cancer cells) (Hillier, S. M.et al, 2009, Cancer Res.
  • Somatostatin also known as growth hormone-inhibiting hormone (GHIH) or somatotropin release-inhibiting factor (SRIF)) or somatotropin re- lease-inhibiting hormone
  • GKIH growth hormone-inhibiting hormone
  • SRIF somatotropin release-inhibiting factor
  • somatotropin re- lease-inhibiting hormone and its analogues such as octreotide (Sandostatin) and lanreotide
  • Asn-Gln-Trp-Ala-Val-Gly-H is-Leu-Met-NH 2 )/gastrin-releasing peptide (GRP) (BB 1, GRP receptor subtype (BB2), the BB3 and BB4) for renal cell, breast, lung, gastric and prostate carcinomas, and neuroblastoma (and neuroblastoma (Ohlsson, B., et al, 1999, Scand. J, Gastroenterology 34 (12): 1224-9; Weber, H. C, 2009, Cur. Opin. Endocri. Diab. Obesity 16(1): 66-71, Gonzalez N, et al, 2008, Cur. Opin. Endocri. Diab. Obesity
  • Neurotensin (NTR1, NTR2, NTR3) for small cell lung cancer
  • Substance P NK1 receptor
  • Neuropeptide Y Y1-Y6
  • Homing Peptides include RGD (Arg-Gly-Asp), NGR (Asn-Gly-Arg), the dimeric and multimeric cyclic RGD peptides (e.g. cRGDfV) that recognize receptors (integrins) on tumor surfaces (Laakkonen P,
  • TAASGVRSMH and LTLRWVGLMS chondroitin sulfate proteoglycan NG2 receptor
  • F3 peptide 31 amino acid peptide that binds to cell surface-expressed nucleolin receptor
  • Peptide Hormones such as luteinizing hormone-releasing hormone (LHRH) agonists and antagonists, and gonadotropin-releasing hormone (GnRH) agonist, acts by targeting follicle stimulating hormone (FSH) and luteinising hormone (LH), as well as testosterone production, e.g. buserelin (Pyr-His-Trp-Ser-Tyr-D-Ser(OtBu)-Leu-Arg-Pro-
  • LHRH luteinizing hormone-releasing hormone
  • GnRH gonadotropin-releasing hormone
  • FSH follicle stimulating hormone
  • LH gonadotropin-releasing hormone
  • testosterone production e.g. buserelin (Pyr-His-Trp-Ser-Tyr-D-Ser(OtBu)-Leu-Arg-Pro-
  • the cell-binding ligands or receptors can be Ig-based and non-Ig-based protein scaf- fold molecules.
  • the Ig-Based scaffolds can be selected, but not limited, from Nanobody (a derivative of VHH (camelid Ig)) (Muyldermans S., 2013 Annu Rev Biochem. 82, 775- 797); Domain antibodies (dAb, a derivative of VH or VL domain) (Holt, L. J, et al, 2003, Trends Biotechnol. 21, 484-490); Bispecific T cell Engager (BiTE, a bispecific diabody) (Baeuerle, P. A, et al, 2009, Curr. Opin. Mol. Ther.
  • Non-Ig scaffolds can be selected, but not limited, from Anticalin (a derivative of Lipocalins) (Skerra A. 2008, FEBS J., 275(11): 2677-2683; Beste G, et al, 1999 Proc. Nat. Acad. USA. 96(5): 1898-1903; Skerra, A. 2000
  • DARPins a derivative of ankrin repeat (AR) proteins
  • AR krin repeat
  • DARPin C9 a derivative of ankrin repeat (AR) proteins
  • DARPin Ec4 a derivative of ankrin repeat (AR) proteins
  • E69_LZ3_E01 a derivative of ankrin repeat (AR) proteins
  • DARPin C9 a derivative of ankrin repeat (AR) proteins
  • DARPin Ec4 DARPin E69_LZ3_E01
  • Winkler J et al, 2009 Mol Cancer Ther. 8(9), 2674-2683
  • Patricia M-K. M. et al, Clin Cancer Res. 2011; 17(1): 100-110
  • Boersma Y. L et al, 2011 J. Biol. Chem. 286(48),41273-41285
  • Avimers a domain A/low-density lipoprotein (LDL) receptor
  • Examples of the structures of the conjugate of the antibody-cell-binding ligands or receptors via the bridge linker are as the following: LB01 (PMSA ligand conjugate), LB02 (Folate receptor conjugate), LB03 (Somatostatin receptor conjugate), LB04 (Octreotide, a
  • Somatostatin analog receptor conjugate LB05 (Lanreoiide, a Somatostatin analog receptor conjugate), LB06 (CAIX receptor conjugate), LB07(CAIX receptor conjugate), LB08 (luteinizing hormone-releasing hormone (LH-RH) ligand and GnRH conjugate), LB09 (luteinizing hormone-releasing hormone (LH-RH) and GnRH ligand conjugate), LB 10 (GnRH antagonist, Abarelix conjugate), LB 11 (cobalamin, VB 12 analog conjugate), LB 12
  • GPPr Gastrin releasing peptide receptor
  • MBA conjugate LB 13 ( ⁇ ⁇ ⁇ 3 integrin receptor, cyclic RGD pentapeptide conjugate), LB 14 (hetero-bivalent peptide ligand for VEGF receptor conjugate), LB 15 (Neuromedin B conjugate), LB 16 (a G-protein coupled receptor, bombesin conjugate) and LB 17 (a Toll-like receptor, TLR 2 conjugate).
  • LB 13 ⁇ ⁇ ⁇ 3 integrin receptor, cyclic RGD pentapeptide conjugate
  • LB 14 hetero-bivalent peptide ligand for VEGF receptor conjugate
  • LB 15 Neuroromedin B conjugate
  • LB 16 a G-protein coupled receptor, bombesin conjugate
  • LB 17 a Toll-like receptor, TLR 2 conjugate.
  • the drugs/ cytotoxic agents used for conjugation via a bridge linker of the present patent can be any analogues and/or derivatives of drugs/molecules described in the present patent.
  • drugs/cytotoxic agents will readily understand that each of the drugs/cytotoxic agents described herein can be modified in such a manner that the resulting compound still retains the specificity and/or activity of the starting compound.
  • the skilled artisan will also understand that many of these compounds can be used in place of the drugs/cytotoxic agents described herein.
  • the drugs/cytotoxic agents of the present invention include analogues and derivatives of the compounds described herein.
  • the azide compound 86 (2.51 g, 9.68 mmol) dissolved in 1,4-dioxane (30 mL) and was added 10 ml of HC1 (conc). The mixture was stirred for 35 min, diluted with EtOH (30 ml) and toluene (30 ml) and evacuated under vacuum. The crude mixture was purified on silica gel using a mixture of methanol (from 5% to 10%) and 1% formic acid in methylene chloride as the eluant to give title compound 87 (1.63 g, 83% yield), ESI MS m/z- C 7 H 12 N 3 O 4 (M-H), cacld. 202.06, found 202.30.
  • Example 7 (4R)-4-(2-((lR,3R)-l-acetoxy-3-((2S,3S)-N,3-dimethyl-2-((R)-l-methyl- piperidine-2-carboxamido)pentanamido)-4-methylpentyl)thiazole-4-carboxamido)-5-(3-(3- (2-( -aminoethoxy)ethoxy)propanamido)-4-hydroxyphenyl)-2-methylpentanoic acid (95).
  • Example 8 4-(benzyloxy)-3-methoxybenzoic acid 4-Hydroxy-3-methoxybenzoic acid (50.0 g, 297.5 mmol) in the mixture of ethanol (350 ml) and NaOH solution (2.0 ML 350 ml) was added BnBr (140.0 g. 823.5 mmol ). The mixture was stirred at 65 °C for 8 h, concentrated, co-evaporated with water (2 x 400 ml) to -400 ml, acidified with 6 M HC1 to pH 3.0, filtered the solid, crystallized with EtOH, dried over the oven at 45 °C with vacuum to afford the title compound (63.6 g, 83% yield). ESI MS m/z+ 281.2 (M + Na).
  • Example 22 (S)-8-((5-(((S)-10-(3-(2-(2-aminoethoxy)ethoxy)propanoyl)-7-methoxy- 2-methylene-5-oxo-2,3 ,5.10.1 1.1 1 a-hexahydro- 1 H-benzo[e]pyrrolo[ 1 ,2-a] [ 1 ,4]diazepin-8- yl)oxy)pentyl)oxy)-7-methoxy-2-methylene-2,3-dihydro- 1 H-benzo[e]pyrrolo[ 1 ,2- a][l,4]diazepin-5(l laH)-one, (100).
  • Boc-L-proline (10.0 g, 46.4 mmol) dissolved in 50 mL THF was cooled to 0 °C, to which BH 3 in THF (1.0 M, 46.4 mL) was added carefully. The mixture was stirred at 0 °C for 1.5 h then poured onto ice water and extracted with ethyl acetate. The organic layer was washed with brine (50 mL), dried over anhydrous Na 2 SO 4 , and concentrated under reduced pressure to give the title compound (8.50 g, 91% yield) as a white solid.
  • n-Butyllithium in hexane (21.6 mL, 2.2 M, 47.43 mmol) was added dropwise at -78 °C to a stirred solution of 4-methyl-5-phenyloxazolidin-2-one (8.0 g, 45.17 mmol) in THF (100 mL) under N 2 .
  • the solution was maintained at -78 ° C for 1 h then propionyl chloride (4.4 mL, 50.59 mmol) was added slowly.
  • the reaction mixture was warmed to -50 °C, stirred for 2 h then quenched by addition of a saturated solution of ammonium chloride (100 mL).
  • oxazoiidinone auxiliary The aqueous phase was acidified to pH 3 with 1N HCl and extracted with ethyl acetate (3 x 50 mL). The organic layer was washed with brine (50 mL), dried over Na 2 SO 4 , filtered and concentrated in vacuo to afford the title compound as colorless oil (1.15 g. 98% yield).
  • the reaction mixture was quenched by addition of 10% aqueous citric acid (5 mL), and acidified to pH 3 with an additional 10% aqueous citric acid (110 mL).
  • the mixture was extracted with ethyl acetate (150 mL x 3).
  • the organic extracts were washed with water (50 mL), saturated aqueous sodium hydrogen carbonate (50 mL), and saturated aqueous sodium chloride (50 mL), dried over Na 2 SO 4 , and concen- trated in vacuo.
  • the residue was purified by column chromatography on silica gel using ethyl acetate/hexane (1:4) as an eluent to give title compound (5.50 g, 93% yield).
  • reaction mixture was then diluted with ethyl acetate (80 mL), washed with 1 N aqueous potassium hydrogen sulfate (40 mL), water (40 mL), saturated aqueous sodium hydrogen carbonate (40 mL), and saturated aqueous sodium chloride (40 mL), dried over Na 2 SO 4 , and concentrated in vacuo.
  • the residue was purified by column chromatography (15-75% ethyl ace- tate/hexanes) to afford the title compound (130 mg, 83% yield) as a white solid.
  • Example 36 (S)-methyl 2-((2R,3R)-3-((S)-l-((3R,4S,5S)-4-((S)-2-((tert- butoxycarbonyl)amino)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)- pyrrolidin-2-yl)-3-methoxy-2-methylpropanamido)-3-phenylpropanoate
  • Boc-Val-OH (51.8 mg, 0.236 mmol) in DCM (5 mL) at 0 °C was added
  • Example 42 (2S)-2-((2R,3R)-3-((2S)-l-((l lS,14S,17S)-l-amino-17-((R)-sec-butyl)- 11 , 14-diisopropyl- 18-methoxy- 10, 16-dimethyl-9, 12, 15-trioxo-3 ,6-dioxa- 10, 13,16- triazaicosan-20-oyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropanamido)-3-phenylpropanoic acid (103).
  • Example 47 Conjugated compound 126 to an antibody for 127.
  • the drug/antibody ratio (DAR) (the combination of PBD dimer and MMAF per antibody) was 3.85, which was determined via UPLC- Qtof mass spectrum. It was 96-99% monomer analyzed by SEC HPLC (Tosoh Bioscience, Tskgel G3000SW, 7.8 mm ID x 30 cm, 0.5 ml/min, 100 min) and a single band measured by SDS-PAGE gel.
  • Example 49 Conjugated compound 128 to an antibody for 129.
  • the drug/antibody ratio (DAR) (the combination of PBD dimer and Tubulysin analog per antibody) was 3.9, which was determined via UPLC-Qtof mass spectrum. It was 96-99% monomer analyzed by SEC HPLC (Tosoh Bioscience, Tskgel G3000SW, 7.8 mm ID x 30 cm, 0.5 ml/min, 100 min) and a single band measured by SDS-PAGE gel. -dioxopyrrolidin-l-yl) 2,3-dibromosuccinate (9)
  • Example 52 Conjugated compound 141 to an antibody for 142.
  • the mixture was purified on G-25 column eluted with 100 mM NaH 2 PO 4 , 50 mM NaCl pH 6.0-7.5 buffer to afford 16.4-17.6 mg of the conjugate compound 92 (82% ⁇ 88% yield) in 13.1-15.2 ml buffer.
  • the drug/antibody ratio (DAR) was 3.9, which was determined via UPLC-Qtof mass spectrum. It was 96-99% monomer analyzed by SEC HPLC (Tosoh Bioscience, Tskgel G3000SW, 7.8 mm ID x 30 cm, 0.5 ml/min, 100 min) and a single band measured by SDS-PAGE gel.
  • Example 53 In vitro cytotoxicity evaluation of conjugates 127, 129 and 142 in comparison with T-DM1:
  • the cell lines used in the cytotoxicity assays were HL-60, a human promyelocytic leukemia cell line; NCI-N87, a human gastric carcinoma cell line; BT-474, a human invasive ductal carcinoma cell line; and SKOV3, a human ovarian carcinoma cell line.
  • HL-60, NCI-N87, and BT-474 cells the cells were grown in RPMI-1640 with 10% FBS.
  • SKOV3 cells the cells were grown in McCoy's 5 A Medium with 10% FBS.
  • the cells 180 ⁇ , 6000 cells
  • the cells were treated with test compounds (20 ⁇ ) at various concentrations in appropriate cell culture medium (total volume, 0.2 mL).
  • the control wells contain cells and the medium but lack the test compounds.
  • the plates were incubated for 120 hours at 37°C with 5% CO 2 .
  • MTT (5 mg/ml) was then added to the wells (20 ⁇ ) and the plates were incubated for 1.5hr at 37°C.
  • the medium was carefully removed and DMSO (180 ⁇ ) was added afterward. After it was shaken for
  • inhibition% [1-(assay-blank)/(control-blank)] x 100.
  • the three new conjugates 127, 129 and 142 were extremely more potent than the commercial conjugate T-DM1.
  • Example 54 Antitumor Activity In vivo.
  • the in vivo efficacy of conjugates 127, 129 and 142 along with T-DM1 were evaluated in a human gastric carcinoma N-87 cell line tumor xenograft models.
  • Five- week-old female BALB/c Nude mice (30 animals) were inoculated subcutaneously in the area under the right shoulder with N-87 carcinoma cells (5 x 10 6 cells/mouse) in 0.1 mL of serum- free medium.
  • the tumors were grown for 8 days to an average size of 133 mm 3 .
  • the animals were then randomly divided into 5 groups (6 animals per group). The first group of mice served as the control group and was treated with the phosphate-buffered saline vehicle.
  • the remaining three groups were treated with conjugates 127, 129, 142 and T- DM1 respectively at dose of 3 mg/Kg administered intravenously.
  • the weight of the animals was also measured at the same time.
  • a mouse was sacrificed when any one of the following criteria was met: (1) loss of body weight of more than 20% from pretreatment weight, (2) tumor volume larger than 1500 mm , (3) too sick to reach food and water, or (4) skin necrosis.
  • a mouse was considered to be tumor-free if no tumor was palpable. The results were plotted in Figure 16. All the four conjugates did not cause the animal body weight loss.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La présente invention concerne de nouvelles séquences de liaison contenant un groupe succinique 2,3-disubstitué, ou un groupe fumarique ou maléique (trans (E)- ou cis (Z) butènedioïque) 2-monosubstitué, ou 2,3-disubstitué, pour la conjugaison d'au moins deux composés/agents cytotoxiques par séquence de liaison à une molécule de liaison cellulaire, au moyen d'une liaison par pontage de paires de thiols sur la molécule de liaison cellulaire de manière spécifique. L'invention concerne également des procédés de préparation de telles séquences de liaison, et d'utilisation de ces séquences de liaison pour la production de conjugués homogènes, ainsi que d'application de ces conjugués dans le traitement de cancers, d'infections et de maladies auto-immunes.
PCT/IB2015/056083 2015-08-10 2015-08-10 Nouvelles séquences de liaison et leurs utilisation pour la conjugaison spécifique de médicaments à une molécule biologique WO2015155753A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2018506984A JP6817288B2 (ja) 2015-08-10 2015-08-10 新規な連結体及び生体分子と薬物との特異的共役におけるその使用
CA2991975A CA2991975C (fr) 2015-08-10 2015-08-10 Nouvelles sequences de liaison et leurs utilisation pour la conjugaison specifique de medicaments a une molecule biologique
CN202210788010.0A CN115300640A (zh) 2015-08-10 2015-08-10 新型连接体及其用于药物和生物分子的特异性偶联
CN201580082582.5A CN108289964B (zh) 2015-08-10 2015-08-10 新型连接体及其用于药物和生物分子的特异性偶联
PCT/IB2015/056083 WO2015155753A2 (fr) 2015-08-10 2015-08-10 Nouvelles séquences de liaison et leurs utilisation pour la conjugaison spécifique de médicaments à une molécule biologique

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2015/056083 WO2015155753A2 (fr) 2015-08-10 2015-08-10 Nouvelles séquences de liaison et leurs utilisation pour la conjugaison spécifique de médicaments à une molécule biologique

Publications (2)

Publication Number Publication Date
WO2015155753A2 true WO2015155753A2 (fr) 2015-10-15
WO2015155753A3 WO2015155753A3 (fr) 2016-06-30

Family

ID=54288492

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2015/056083 WO2015155753A2 (fr) 2015-08-10 2015-08-10 Nouvelles séquences de liaison et leurs utilisation pour la conjugaison spécifique de médicaments à une molécule biologique

Country Status (4)

Country Link
JP (1) JP6817288B2 (fr)
CN (2) CN115300640A (fr)
CA (1) CA2991975C (fr)
WO (1) WO2015155753A2 (fr)

Cited By (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016059622A3 (fr) * 2016-02-04 2016-12-08 Suzhou M-Conj Biotech Co., Ltd. Lieurs de conjugaison spécifique, immunoconjugués spécifiques de ceux-ci, procédés de fabrication et utilisations desdits conjugués de ceux-ci
WO2017059289A1 (fr) 2015-10-02 2017-04-06 Genentech, Inc. Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
CN106957235A (zh) * 2016-04-19 2017-07-18 福安药业集团宁波天衡制药有限公司 一种他莫昔芬的制备方法
CN108586556A (zh) * 2018-01-17 2018-09-28 浙江海正药业股份有限公司 一种喷司他丁的新晶型及其制备方法和用途
WO2018178076A1 (fr) * 2017-03-29 2018-10-04 F. Hoffmann-La Roche Ag Molécule bispécifique de liaison à l'antigène pour un récepteur de co-stimulation du tnf
CN109689107A (zh) * 2016-04-20 2019-04-26 杭州多禧生物科技有限公司 鹅膏毒素的衍生物及其与细胞结合分子的偶联
WO2019109415A1 (fr) * 2017-12-04 2019-06-13 清华大学 Composé de dégradation ciblée de hmgcr et son application
CN109956972A (zh) * 2017-12-22 2019-07-02 四川科瑞德凯华制药有限公司 塞替派晶型i及其制备方法和用途
KR20190085532A (ko) * 2016-11-14 2019-07-18 항저우 디에이씨 바이오테크 씨오, 엘티디 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
WO2020019108A1 (fr) * 2018-07-23 2020-01-30 Guangzhou Othrotx Co., Ltd. Conjugués médicamenteux à base de bisphosphonate
WO2020033200A1 (fr) * 2018-08-09 2020-02-13 Siemens Healthcare Diagnostics Inc. Composition d'une matière première de bilirubine et son procédé de préparation
WO2020081493A1 (fr) 2018-10-16 2020-04-23 Molecular Templates, Inc. Protéines de liaison pd-l1
CN111093707A (zh) * 2017-12-31 2020-05-01 杭州多禧生物科技有限公司 含支链连接体的Tubulysin同系物偶联物
US10675358B2 (en) 2016-07-07 2020-06-09 The Board Of Trustees Of The Leland Stanford Junior University Antibody adjuvant conjugates
US10772970B2 (en) 2017-12-01 2020-09-15 Abbvie Inc. Glucocorticoid receptor agonist and immunoconjugates thereof
WO2021000067A1 (fr) 2019-06-29 2021-01-07 杭州多禧生物科技有限公司 Conjugué molécule de liaison cellulaire-dérivé de tubulysine et méthode de préparation associée
CN112285361A (zh) * 2020-09-27 2021-01-29 中国人民解放军空军军医大学 排除抗-cd38单克隆抗体药物对抗人球蛋白检测干扰的试剂
WO2021055816A1 (fr) 2019-09-18 2021-03-25 Molecular Templates, Inc. Molécules de liaison pd-l1 comprenant des échafaudages de la sous-unité a de la shiga-toxine
US10973826B2 (en) 2015-10-29 2021-04-13 Novartis Ag Antibody conjugates comprising toll-like receptor agonist
CN112675305A (zh) * 2021-01-22 2021-04-20 中国科学院深圳先进技术研究院 用于肿瘤治疗的双亲性分子自组装纳米药物及制备方法和用途
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
CN114072178A (zh) * 2019-04-11 2022-02-18 索尼集团公司 可编程的聚合药物
CN114106088A (zh) * 2021-04-28 2022-03-01 联宁（苏州）生物制药有限公司 基于溴甲基吡嗪的药物偶联物及adc
WO2022051591A2 (fr) 2020-09-04 2022-03-10 Novarock Biotherapeutics, Ltd. Anticorps anti-nectine-4 et leurs utilisations
CN114533669A (zh) * 2022-01-18 2022-05-27 武汉大学 一种口腔护理组合物及其制备方法和应用
US11400164B2 (en) 2019-03-15 2022-08-02 Bolt Biotherapeutics, Inc. Immunoconjugates targeting HER2
WO2022078524A3 (fr) * 2021-11-03 2022-08-25 Hangzhou Dac Biotech Co., Ltd. Conjugaison spécifique d'un anticorps
WO2022197945A1 (fr) 2021-03-17 2022-09-22 Molecular Templates, Inc. Protéines de liaison pd-l1 comprenant des échafaudages de sous-unité a de shigatoxine et des antigènes de lymphocytes t cd8+
US11583590B2 (en) 2017-09-29 2023-02-21 Daiichi Sankyo Company, Limited Antibody-pyrrolobenzodiazepine derivative conjugate and method of use thereof for treating a tumor
US11826430B2 (en) 2019-05-14 2023-11-28 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
US11834458B2 (en) 2021-03-23 2023-12-05 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
WO2024073106A1 (fr) * 2022-09-29 2024-04-04 Tract Pharmaceuticals, Inc. Composés et compositions utiles en tant qu'inhibiteurs de taps
US11952349B2 (en) 2019-11-13 2024-04-09 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
US12006314B2 (en) 2021-05-03 2024-06-11 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
US12018159B2 (en) 2017-07-27 2024-06-25 Sony Group Corporation Ultra bright dimeric or polymeric dyes and methods for preparation of the same

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7330515B2 (ja) * 2015-08-10 2023-08-22 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ． 新規な連結体及び生体分子と薬物との特異的共役におけるその使用
WO2020073345A1 (fr) * 2018-10-12 2020-04-16 Hangzhou Dac Biotech Co., Ltd Lieurs de conjugaison contenant un groupe 2,3-diaminosuccinyle
AU2019379418A1 (en) 2018-11-14 2021-06-03 Daiichi Sankyo Company, Limited Anti-CDH6 antibody-pyrrolobenzodiazepine derivative conjugate
US20220125934A1 (en) * 2018-12-07 2022-04-28 Oxford University Innovation Limited Linkers
CN114430738A (zh) * 2019-04-11 2022-05-03 索尼集团公司 可编程的聚合药物
CN110256313B (zh) * 2019-05-15 2021-01-29 江苏省原子医学研究所 一种光敏剂前药化合物及其制备方法和应用
EP3986463A4 (fr) * 2019-06-24 2023-03-15 Hangzhou Dac Biotech Co., Ltd. Conjugué d'un agent cytotoxique à une molécule de liaison cellulaire avec des lieurs ramifiés
CN110508029B (zh) * 2019-09-04 2022-01-28 武玉香 一种用于同时提取氟苯尼考、氯霉素、甲砜霉素的免疫亲和柱
WO2021170093A1 (fr) * 2020-02-26 2021-09-02 上海科技大学 Application de disulfirame dans la résistance contre le coronavirus
CN111393346B (zh) * 2020-06-02 2020-08-25 凯莱英生命科学技术(天津)有限公司 N-Boc-Dolaproine及Boc-Dap DCHA的合成方法
CN114478420A (zh) * 2020-11-13 2022-05-13 北京大学 多特异生物偶联连接臂及其合成方法
CN114605367B (zh) * 2020-12-03 2023-06-27 中国人民解放军军事科学院军事医学研究院 含香豆素的连接子及含该连接子的抗体偶联药物
CN112535678A (zh) * 2020-12-28 2021-03-23 烟台大学 连接曲妥珠单抗的美登素纳米粒组合物
CN112675313A (zh) * 2020-12-28 2021-04-20 烟台大学 连接曲妥珠单抗片段的美登素纳米粒组合物
CN116754760B (zh) * 2023-06-14 2024-01-26 之江实验室 2,4-二硝基苯酚(dnp)与抗体可控断裂偶联的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL45594A (en) * 1973-11-12 1977-12-30 Stauffer Chemical Co Bis-substituted succinamides and their use as herbicides
CA2775350A1 (fr) * 2009-09-24 2011-03-31 Seattle Genetics, Inc. Conjugues ligand-medicament dr5
KR20140139480A (ko) * 2011-12-05 2014-12-05 이제니카 바이오테라퓨틱스, 인크. 항체-약물 접합체 및 관련 화합물, 조성물, 및 방법
EP2822597A1 (fr) * 2012-03-09 2015-01-14 UCL Business Plc. Modification chimique d'anticorps
ES2939836T3 (es) * 2012-07-12 2023-04-27 Hangzhou Dac Biotech Co Ltd Conjugados de moléculas de unión celular con agentes citotóxicos
EP2922818B1 (fr) * 2012-11-24 2018-09-05 Hangzhou Dac Biotech Co., Ltd Lieurs hydrophiles et leurs utilisations pour la conjugaison de médicaments à des molécules se liant aux cellules
WO2014197854A1 (fr) * 2013-06-06 2014-12-11 Igenica Biotherapeutics, Inc. Nouveaux lieurs pour conjugués anticorps-médicament et composés connexes, compositions, et procédés d'utilisation
WO2015113476A1 (fr) * 2014-01-29 2015-08-06 上海恒瑞医药有限公司 Conjugué de médicaments cytotoxiques et de ligands, son procédé de préparation et ses applications
EP3317246A4 (fr) * 2015-07-04 2019-02-27 Suzhou M-conj Biotech Co., Ltd. Conjugaison spécifique d'une molécule de liaison cellulaire

Cited By (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017059289A1 (fr) 2015-10-02 2017-04-06 Genentech, Inc. Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
US10973826B2 (en) 2015-10-29 2021-04-13 Novartis Ag Antibody conjugates comprising toll-like receptor agonist
US11779663B2 (en) 2016-02-04 2023-10-10 Hangzhou Dac Biotech Co., Ltd. Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof
WO2016059622A3 (fr) * 2016-02-04 2016-12-08 Suzhou M-Conj Biotech Co., Ltd. Lieurs de conjugaison spécifique, immunoconjugués spécifiques de ceux-ci, procédés de fabrication et utilisations desdits conjugués de ceux-ci
US11129910B2 (en) 2016-02-04 2021-09-28 Hangzhou Dac Biotech Co., Ltd. Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof
CN106957235A (zh) * 2016-04-19 2017-07-18 福安药业集团宁波天衡制药有限公司 一种他莫昔芬的制备方法
CN109689107A (zh) * 2016-04-20 2019-04-26 杭州多禧生物科技有限公司 鹅膏毒素的衍生物及其与细胞结合分子的偶联
CN109689107B (zh) * 2016-04-20 2022-08-16 杭州多禧生物科技有限公司 鹅膏毒素的衍生物及其与细胞结合分子的偶联
US10675358B2 (en) 2016-07-07 2020-06-09 The Board Of Trustees Of The Leland Stanford Junior University Antibody adjuvant conjugates
US11547761B1 (en) 2016-07-07 2023-01-10 The Board Of Trustees Of The Leland Stanford Junior University Antibody adjuvant conjugates
US11110178B2 (en) 2016-07-07 2021-09-07 The Board Of Trustees Of The Leland Standford Junior University Antibody adjuvant conjugates
KR102459468B1 (ko) 2016-11-14 2022-10-26 항저우 디에이씨 바이오테크 씨오, 엘티디 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
JP2022188016A (ja) * 2016-11-14 2022-12-20 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ． 共役連結体、該連結体を含有する細胞結合分子－薬物共役体、並びに該共役体及び連結体の使用及び製造方法
KR20210126795A (ko) * 2016-11-14 2021-10-20 항저우 디에이씨 바이오테크 씨오, 엘티디 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
JP7138350B2 (ja) 2016-11-14 2022-09-16 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ． 共役連結体、該連結体を含有する細胞結合分子－薬物共役体、並びに該共役体及び連結体の使用及び製造方法
EP3888691A1 (fr) 2016-11-14 2021-10-06 Hangzhou Dac Biotech Co., Ltd. Lieurs de conjugaison, conjugués médicament-molécule de liaison à une cellule contenant lesdits lieurs, procédés de préparation et d'utilisation de tels conjugués avec les lieurs
EP3538080A4 (fr) * 2016-11-14 2020-07-08 Hangzhou Dac Biotech Co., Ltd. Lieurs de conjugaison, conjugués médicament-molécule de liaison à une cellule contenant lesdits lieurs, procédés de préparation et d'utilisation de tels conjugués avec les lieurs
KR20190085532A (ko) * 2016-11-14 2019-07-18 항저우 디에이씨 바이오테크 씨오, 엘티디 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
KR102459469B1 (ko) 2016-11-14 2022-10-26 항저우 디에이씨 바이오테크 씨오, 엘티디 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
KR102345175B1 (ko) 2016-11-14 2021-12-31 항저우 디에이씨 바이오테크 씨오, 엘티디 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
KR20210126796A (ko) * 2016-11-14 2021-10-20 항저우 디에이씨 바이오테크 씨오, 엘티디 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
JP2019536772A (ja) * 2016-11-14 2019-12-19 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ．Ｈａｎｇｚｈｏｕ Ｄａｃ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． 共役連結体、該連結体を含有する細胞結合分子−薬物共役体、並びに該共役体及び連結体の使用及び製造方法
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
WO2018178076A1 (fr) * 2017-03-29 2018-10-04 F. Hoffmann-La Roche Ag Molécule bispécifique de liaison à l'antigène pour un récepteur de co-stimulation du tnf
CN110382542A (zh) * 2017-03-29 2019-10-25 豪夫迈·罗氏有限公司 针对共刺激性tnf受体的双特异性抗原结合分子
US11453722B2 (en) 2017-03-29 2022-09-27 Hoffmann La-Roche Inc. Bispecific antigen binding molecule for a costimulatory TNF receptor
US12018159B2 (en) 2017-07-27 2024-06-25 Sony Group Corporation Ultra bright dimeric or polymeric dyes and methods for preparation of the same
US11583590B2 (en) 2017-09-29 2023-02-21 Daiichi Sankyo Company, Limited Antibody-pyrrolobenzodiazepine derivative conjugate and method of use thereof for treating a tumor
US11628223B2 (en) 2017-09-29 2023-04-18 Daiichi Sankyo Company, Limited Antibody-drug conjugates comprising substituted benzo[e]pyrrolo[1,2-α][1,4]diazepines
US10772970B2 (en) 2017-12-01 2020-09-15 Abbvie Inc. Glucocorticoid receptor agonist and immunoconjugates thereof
WO2019109415A1 (fr) * 2017-12-04 2019-06-13 清华大学 Composé de dégradation ciblée de hmgcr et son application
CN109956972A (zh) * 2017-12-22 2019-07-02 四川科瑞德凯华制药有限公司 塞替派晶型i及其制备方法和用途
CN111093707A (zh) * 2017-12-31 2020-05-01 杭州多禧生物科技有限公司 含支链连接体的Tubulysin同系物偶联物
CN108586556B (zh) * 2018-01-17 2021-04-20 浙江海正药业股份有限公司 一种喷司他丁的晶型及其制备方法和用途
CN108586556A (zh) * 2018-01-17 2018-09-28 浙江海正药业股份有限公司 一种喷司他丁的新晶型及其制备方法和用途
WO2020019108A1 (fr) * 2018-07-23 2020-01-30 Guangzhou Othrotx Co., Ltd. Conjugués médicamenteux à base de bisphosphonate
US11460475B2 (en) 2018-08-09 2022-10-04 Siemens Healthcare Diagnostics Inc. Composition of a bilirubin stock and a method of preparation thereof
WO2020033200A1 (fr) * 2018-08-09 2020-02-13 Siemens Healthcare Diagnostics Inc. Composition d'une matière première de bilirubine et son procédé de préparation
WO2020081493A1 (fr) 2018-10-16 2020-04-23 Molecular Templates, Inc. Protéines de liaison pd-l1
US11400164B2 (en) 2019-03-15 2022-08-02 Bolt Biotherapeutics, Inc. Immunoconjugates targeting HER2
CN114072178A (zh) * 2019-04-11 2022-02-18 索尼集团公司 可编程的聚合药物
US11826430B2 (en) 2019-05-14 2023-11-28 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
WO2021000067A1 (fr) 2019-06-29 2021-01-07 杭州多禧生物科技有限公司 Conjugué molécule de liaison cellulaire-dérivé de tubulysine et méthode de préparation associée
WO2021055816A1 (fr) 2019-09-18 2021-03-25 Molecular Templates, Inc. Molécules de liaison pd-l1 comprenant des échafaudages de la sous-unité a de la shiga-toxine
US11952349B2 (en) 2019-11-13 2024-04-09 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
WO2022051591A2 (fr) 2020-09-04 2022-03-10 Novarock Biotherapeutics, Ltd. Anticorps anti-nectine-4 et leurs utilisations
CN112285361A (zh) * 2020-09-27 2021-01-29 中国人民解放军空军军医大学 排除抗-cd38单克隆抗体药物对抗人球蛋白检测干扰的试剂
CN112285361B (zh) * 2020-09-27 2023-12-05 中国人民解放军空军军医大学 排除抗-cd38单克隆抗体药物对抗人球蛋白检测干扰的试剂
CN112675305A (zh) * 2021-01-22 2021-04-20 中国科学院深圳先进技术研究院 用于肿瘤治疗的双亲性分子自组装纳米药物及制备方法和用途
WO2022197945A1 (fr) 2021-03-17 2022-09-22 Molecular Templates, Inc. Protéines de liaison pd-l1 comprenant des échafaudages de sous-unité a de shigatoxine et des antigènes de lymphocytes t cd8+
US11834458B2 (en) 2021-03-23 2023-12-05 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
CN114106088A (zh) * 2021-04-28 2022-03-01 联宁（苏州）生物制药有限公司 基于溴甲基吡嗪的药物偶联物及adc
US12006314B2 (en) 2021-05-03 2024-06-11 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
WO2023078273A1 (fr) * 2021-11-03 2023-05-11 Hangzhou Dac Biotech Co., Ltd. Conjugaison spécifique pour un conjugué anticorps-médicament
WO2022078524A3 (fr) * 2021-11-03 2022-08-25 Hangzhou Dac Biotech Co., Ltd. Conjugaison spécifique d'un anticorps
CN114533669A (zh) * 2022-01-18 2022-05-27 武汉大学 一种口腔护理组合物及其制备方法和应用
CN114533669B (zh) * 2022-01-18 2022-11-04 武汉大学 一种口腔护理组合物及其制备方法和应用
WO2024073106A1 (fr) * 2022-09-29 2024-04-04 Tract Pharmaceuticals, Inc. Composés et compositions utiles en tant qu'inhibiteurs de taps

Also Published As

Publication number Publication date
CN108289964A (zh) 2018-07-17
JP2018532695A (ja) 2018-11-08
WO2015155753A3 (fr) 2016-06-30
CA2991975A1 (fr) 2015-10-15
CN115300640A (zh) 2022-11-08
JP6817288B2 (ja) 2021-01-20
CN108289964B (zh) 2022-08-12
CA2991975C (fr) 2021-04-06

Similar Documents

Publication Publication Date Title
US11779663B2 (en) Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof
US20220323602A1 (en) Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers
US10328157B2 (en) Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
CA2991975C (fr) Nouvelles sequences de liaison et leurs utilisation pour la conjugaison specifique de medicaments a une molecule biologique
US10307391B2 (en) Disulfur bridge linkers for conjugation of a cell-binding molecule
AU2022206809A1 (en) Bridge Linkers for Conjugation of Cell-Binding Molecules
CA2991384A1 (fr) Liants de pont servant a la conjugaison d'une molecule liant une cellule
CA2989269A1 (fr) Lieurs hydrophiles pour la conjugaison d'un agent cytotoxique ou d'une molecule chromophore a une molecule de fixation
NZ744940B2 (en) Conjugation linkers, antibody-drug conjugates thereof, and methods of synthesis and use of such conjugates

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2991975

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2018506984

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15776256

Country of ref document: EP

Kind code of ref document: A2